Effect of Nonsurgical Periodontal Therapy on C-Reactive Protein and Iron Indices in Haemodialysis Patients with Chronic Periodontitis by Sheethel Menon, V
EFFECT OF NONSURGICAL PERIODONTAL THERAPY 
ON C-REACTIVE PROTEIN AND IRON INDICES IN 
HAEMODIALYSIS PATIENTS WITH CHRONIC 
PERIODONTITIS 
 
DISSERTATION 
 
Submitted to The Tamil Nadu Dr. M.G.R Medical University 
in partial fulfilment of the requirement for the degree of 
 
MASTER OF DENTAL SURGERY 
 
 
BRANCH II 
PERIODONTOLOGY 
2014 - 2017 
SREE MOOKAMBIKA INSTITUTE OF DENTAL  
SCIENCES, KULASEKHARAM 
ENDORSEMENT BY THE PRINCIPAL / HEAD OF THE  
INSTITUTION 
 
 This is to certify that the dissertation entitled “Effect of nonsurgical 
periodontal therapy on C-reactive protein and iron indices in haemodialysis 
patients with chronic periodontitis” is a bonafide research work done by                        
Dr. Sheethel Menon V under the guidance of Dr. Arun Sadasivan, M.D.S, Professor, 
Department of Periodontics, Sree Mookambika Institute of Dental Sciences, 
Kulasekharam.  
 
 
 
 Dr. Elizabeth Koshi, MDS, 
 PRINCIPAL 
 Sree Mookambika Instituteof Dental Sciences, 
 V.P.M Hospital Complex, 
 Padanilam, 
 Kulasekharam, 
 Kanyakumari District,  
 Tamil Nadu - 629161 
 
CERTIFICATE 
 This is to certify that the dissertation titled “Effect of nonsurgical 
periodontal therapy on C-reactive protein and iron indices in haemodialysis 
patients with chronic periodontitis” is a bonafide record of the work done by              
Dr. Sheethel Menon V, Post graduate student during the period  
2014-2017 under our guidance and supervision. The dissertation is submitted to 
THE TAMIL NADU DR.M.G.R MEDICAL UNIVERSITY, CHENNAI, in 
partial fulfilment of the requirement for the award of the Degree of MASTER OF 
DENTAL SURGERY IN PERIODONTOLOGY, BRANCH II. It has not been 
submitted (partial or full) for the award of any other degree or diploma. 
 
 
 
 
. 
 
 
 
 
 
GUIDE 
Dr Arun Sadasivan, MDS 
Professor, 
Department of Periodontics 
Sree Mookambika Institute of Dental 
Sciences, Kulasekharam 629161 
CO GUIDE 
Dr. Elizabeth Koshi, MDS 
Head of the Department, 
Department of Periodontics 
Sree Mookambika Institute of Dental 
Sciences, Kulasekharam 629161 
CO GUIDE 
Dr. Beena Unnikrishnan 
Associate Professor  
Department of General Medicine 
Sree Mookambika Institute of Medical 
Sciences,  Kulasekharam, 629161 
 
ACKNOWLEDGEMENT 
I bow in gratitude to the Almighty God, for showering upon me His 
blessings that gave me the courage to venture out this thesis. 
My foremost thanks to my guide, Dr. Arun Sadasivan MDS, Professor for 
his invaluable guidance, constant encouragement, immense patience and everlasting 
inspiration in every step of my research work. 
I am ever grateful to my co-guide, Dr. Elizabeth Koshi MDS, Principal, 
Professor & Head Department of Periodontics, Sree Mookambika Institute of Dental 
Sciences for her valuable insight, suggestions and meticulous supervision which 
shaped this work. 
I am very grateful to my co-guide, Dr Beena Unnikrishnan, MBBS, DNB 
for giving her valuable guidance, suggestions and inspiration throughout my thesis 
work.  
 I submit my bouquet of thanks to Dr. C.K. Velayuthan Nair  MBBS, MS., 
Chairman, Dr. Rema V Nair MBBS, MD, DGO., Director, Dr. Vinu Gopinath MS, Mch. 
and Dr. R.V. Mookambika MD, DM., Trustees Sree Mookambika Institute of 
Dental Sciences for the sanction of resources and facilitating the conduct of my 
project. 
I would like to acknowledge Dr. Anu Fernz MDS, Dr. Nikhil Das MDS, 
Dr. Shilpa Jayakumar MDS in the Department of Periodontics, for their practical 
advice and constant encouragement. 
I would like to acknowledge the staffs of Central Lab and Dialysis Unit, 
Sree Mookambika Institute of Medical Science for their constant help provided. 
I am thankful to Dr. Sarath Babu for providing me with his timely 
statistical analysis involved in this study. 
I gratefully acknowledge my batchmate Dr. Vishnu JS and my fellow Post 
graduates Dr. Shamna, Dr. Anju, Dr. Anina, and Dr. Blessing who have 
supported through their encouraging words. 
With deep sense of gratitude, I remember the love, support and 
encouragement I received from my family especially my daughter Mayukha whose 
smile made me keep going forward throughout the thesis. 
A final but weighty word of thanks to my beloved husband Manoj V Pillai, 
my pillar of support, who always encouraged me and made me feel that I can 
complete this research work.  
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
Sl. No Index Page No 
1.  List of Abbreviations i 
2.  List of Tables iii 
3.  List of Graphs iv 
4.  List of Colour Plates v 
5.  List of Annexure vi 
6.  Abstract vii 
7.  Introduction 1 
8.  Aims and Objectives 5 
9.  Review of literature 6 
10.  Materials and Methods 33 
11.  Results and Observations 42 
12.  Discussion 62 
13.  Summary and Conclusion 69 
14.  Bibliography ix 
15.  Annexure  
 
i 
 
LIST OF ABBREVIATIONS 
AAP - American Academy of Periodontology 
BOP -  Bleeding on Probing 
CAL - Clinical attachment level 
CAPD - Continuous ambulatory peritoneal dialysis 
CDC - Centre for Disease Control and Prevention 
CKD - Chronic Kidney Disease 
Cre-S - Serum creatinine levels 
CRP - C - reactive protein 
CVD - Cardiovascular disease 
DMFT - Decayed, Missing or Filled Teeth index 
DN - Diabetic nephropathy 
ESA - Erythropoiesis-stimulating agents 
ESR - Erythrocyte Sedimentation Rate 
ESRD - End Stage Renal Disease 
eGFR - Estimated Glomerular Filtration Rate 
GI - Gingival index 
GR - Gingival recession 
Hb - Haemoglobin 
HDL - High Density lipoprotein 
IL-1β - Interleukin-1 beta 
KDIGO - Kidney Disease: Improving Global Outcomes 
K/DOQI  - Kidney Disease Outcomes Quality Initiative 
LDL - Low density lipoprotein 
LPA - Loss of periodontal attachment 
ii 
 
NHANES - National Health and Nutrition Examination Survey 
NSPT - Non-surgical periodontal therapy 
OHI-S - Oral hygiene index- Simplified 
PAI-1 - Plasminogen-Activator Inhibitor-1 
PD - Peritoneal Dialysis 
PI - Plaque index 
PPD - Probing pocket depth 
S-OC - Serum osteocalcin 
TDI - Total dental index 
TIBC - Total iron-binding capacity 
TNF-α - Tumor Necrosis Factor-alpha 
TSAT - Transferrin saturation 
U-DPD - Urinary deoxypyridinoline 
 
 
 
 
 
 
 
 
 
iii 
 
LIST OF TABLES 
Table No Title 
Table 1 Comparison of demographic, vital signs and clinical observations between the groups 
Table 2 Comparison of mean periodontal parameters at T0 between the groups 
Table 3 Comparison of mean periodontal parameters at T1 between the groups 
Table 4 Comparison of mean periodontal parameters at T2 between the groups 
Table 5 Comparison of mean periodontal parameters of Group-I at different time periods 
Table 6 Comparison of mean periodontal parameters of Group-II at different time periods 
Table 7 Comparison of mean periodontal parameters of Group-III at different time periods 
Table 8 Comparison of mean CRP, Iron, TIBC and TSAT values between the groups at T0 time 
Table 9 Comparison of mean CRP, Iron, TIBC and TSAT values between the groups at T2 time 
Table 10 Comparison of mean CRP, Iron, TIBC and TSAT values of Group-I between T0 and T2 
Table 11 Comparison of mean CRP, Iron, TIBC and TSAT values of Group-II between T0 and T2 
Table 12 Comparison of mean CRP, Iron, TIBC and TSAT values of Group-III between T0 and T2 
Table 13 Comparison of mean renal and haematological parameters between the groups at T0 time 
Table 14 Comparison of mean renal and haematological parameters between the groups at T2 time 
Table 15 Comparison of mean renal and haematological parameters within the Group-I at different time periods 
Table 16 Comparison of mean renal and haematological parameters within the Group-II at different time periods 
Table 17 Comparison of mean renal and haematological parameters within the Group-III at different time periods 
Table 18 Comparison of mean creatinine and GFR values between the groups at T0 
and T2 time 
Table 19 Comparison of mean creatinine and GFR values within the groups at different time periods 
iv 
 
LIST OF GRAPHS 
Graph No Title 
Graph 1 Comparison of mean Plaque Index values of different groups 
Graph 2 Comparison of mean Gingival Index between the groups 
Graph 3 Comparison of mean Bleeding on Probing values of different groups 
Graph 4 Comparison of mean Probing Pocket Depth between the groups 
Graph 5 Comparison of mean Clinical Attachment Level between the groups 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF COLOUR PLATES 
Colour plate No. Title  
1 Armamentarium for scaling and root planing 
2 Blood collection 
3 Centrifugation 
4 Collected serum sample 
5 Autoanalyzer to measure C-reactive protein 
6 Reagents in the Autoanalyzer 
7 
Beckman Coulter AU 480 Fully automated analyzer for 
estimation of Serum iron, TIBC, serum creatinine and 
albumin 
8 
Samples placed in the sample holder for estimation of serum 
ferritin 
9 Reagents loaded in the analyzer 
10 
Beckman Coulter Access 2 Immunoassay System for 
estimation of serum ferritin 
11 
Beckman Coulter fully automated analyzer for haemoglobin 
estimation and ESR 
 
 
 
 
 
vi 
 
LIST OF ANNEXURE 
Annexure No. Title  
Annexure-1 Certificate from Institutional Research Committee 
Annexure-2 Certificate from Institutional Human Ethics Committee 
Annexure-3 Patients Information sheet 
-English 
-Malayalam 
-Tamil 
Annexure-4 Patient Consent form 
-English 
-Malayalam 
-Tamil 
Annexure-5 Case Record form 
Annexure-6 Each group individual clinical, renal and haematological 
parameters obtained. 
 
     
 
 
 
 
 
 
 
 
 
ABSTRACT 
Abstract 
   vii 
 
 
 
Background 
Periodontitis is a chronic inflammatory disease which leads to the destruction 
of the supporting tissues of the teeth. Interaction between periodontal pathogens and 
host immune response can trigger inflammatory mediators. These inflammatory 
cytokines have been reported to decrease the release of erythropoietin from kidney 
and thereby can lead to anemia. Periodontitis is found to increase the systemic 
inflammatory burden possibly facilitated by acute phase reactants like C-reactive 
protein (CRP), which aggravates the existing metabolic conditions like diabetes, 
hypertension and anemia in chronic kidney disease patients undergoing 
haemodialysis. Evaluation of anemia associated with chronic diseases can be done 
by the estimation of serum iron, total iron binding capacity, transferrin saturation 
and serum ferritin. 
Aim of the study 
To evaluate oral health status, clinical, renal and haematological parameters 
in systemically healthy chronic periodontitis patients and chronic kidney disease 
patients undergoing haemodialysis of varying duration and to evaluate effect of non-
surgical periodontal therapy on clinical, renal and haematological parameters at 
baseline and 3 months postoperatively. 
Materials and Methods 
This was a comparative interventional study which included sixty chronic 
periodontitis patients. These chronic periodontitis patients were divided into three 
groups which consisted of chronic kidney disease patients undergoing haemodialysis 
for less than a year (Group I), chronic kidney disease patients undergoing 
haemodialysis for more than a year (Group II) and systemically healthy chronic 
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periodontitis patients (Group III).  Clinical parameters were recorded at baseline, 1 
month and 3 months after nonsurgical periodontal therapy. C reactive protein (CRP), 
transferrin saturation (TSAT) and serum ferritin was observed at baseline and 3 
months after nonsurgical periodontal therapy. 
Results 
The clinical parameters like Plaque index, Gingival index, Bleeding on 
Probing, Probing Pocket Depth and Clinical Attachment level showed pronounced 
reduction at the end of 3 months in all the groups. CRP reduced in all the three 
groups 3 months post-operatively, but statistically significant reduction was seen in 
Group I and group III only. TSAT increased significantly in all the three groups. 
With regard to serum ferritin, it was seen that serum ferritin increased significantly 
in Group I and Group II, whereas significant reduction was seen in Group III.  
Conclusion 
It was seen that clinical parameters reduced in both systemically healthy 
periodontitis patients as well as chronic periodontitis patients undergoing 
haemodialysis of varying duration. It was noted that nonsurgical periodontal therapy 
can bring about reduction in CRP level and also improvement in iron indices in 
systemically healthy periodontitis patients and also in chronic kidney disease 
patients undergoing haemodialysis of varying duration. However studies with larger 
sample size and longer duration of follow up are required to confirm the findings. 
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Periodontitis is defined as an inflammatory disease of the supporting tissues 
of the teeth caused by specific microorganisms or groups of specific 
microorganisms, resulting in progressive destruction of the periodontal ligament and 
alveolar bone with increased probing depth formation, recession, or both.1 The 
microorganisms which are responsible for initiation and progression of periodontal 
diseases colonize the tooth surface and also at/or below the gingival margin and 
epithelial surfaces.2 There is a wide variation in the bacterial species in the 
subgingival plaque. Plaque induced gingival disease generally consist of gram 
positive aerobic species, whereas there is a predominance of gram negative species 
in plaque samples of chronic periodontitis patients with almost 85% anaerobic or 
facultative anaerobic species.3 
Biofilm formation and its persistence on the tooth surface present a challenge 
to the oral, sulcular and junctional epithelia.4  The host epithelial cells are triggered by 
bacterial enzymes, endotoxins and exotoxins, bacterial waste products and surface 
components which secrete proinflammatory cytokines. Host immune response to these 
bacteria in biofilm is by the cooperation of innate and acquired immune system. Even 
though periodontitis is a chronic inflammatory disease, agents of acute phase of 
inflammation like C-reactive protein (CRP), plasminogen-activator inhibitor 1(PAI-1) 
and fibrinogen, which belong to innate immune system are also involved in the 
disease. This cause the activation of complement system, neutralization of 
pathogenesis agents, stimulation of repair system and degeneration of different 
tissues.5 The relationship between periodontitis and systemic disease(periodontal 
medicine) is a two-way relationship with systemic host factors acting locally to affect 
periodontal destruction and the local bacterial challenge generating a widespread 
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effects with the potential to induce adverse systemic outcome.6 Periodontal disease 
lead to a transient increase in the circulating levels of Interleukin -1β (IL-1β), Tumor 
Necrosis Factor- α (TNF-α) and Prostaglandin E2. This can be considered as 
contribution of periodontal disease to systemic inflammation.7  
Kidney performs four essential functions like excretion of end products of 
metabolism (like urea), regulation of blood volume and electrolyte concentration, 
regulation of erythrocyte production in the bone marrow through the secretion of 
erythropoietin and participation in calcium homeostasis through hydroxylation of 
vitamin D3 into active or inactive metabolites.8 Renal function can be assessed by the 
measurement of Glomerular Filtration Rate (GFR). Chronic Kidney Disease (CKD) is 
defined according to the presence or absence of kidney damage and the level of 
kidney function-irrespective of the type of type of kidney disease.  The normal level of 
GFR may vary based on the age, gender and body size. The normal mean GFR for 
young adults is approximately 120-130mL/min/1.73m2.9 All the individuals with GFR 
<60mL/min/1.73m2 for ≥3 months are classified as having chronic kidney disease, 
irrespective of the presence or absence of kidney damage. Chronic renal failure is 
characterized by a gradual reduction in the number of functional nephrons. Due to 
progressive renal damage, the excretion of body metabolic waste products is impaired, 
resulting in a state of intoxication called uremia, which is characterized by increased 
levels of acute phase proteins(like CRP), certain cytokines, and even macrophages.10 
Chronic renal failure can lead to terminal or End stage renal disease(ESRD). In these 
patients kidney function has deteriorated to a point where body suffers chronic 
systemic abnormalities. In such cases renal replacement therapy is required in the 
form of dialysis and/or kidney transplantation.11 
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Patients with ESRD are at higher risk of developing cardiovascular 
complications like atherosclerosis due to factors like diabetes, hypertension, 
dislipidemia, inflammation, malnutrition, and predisposition to infection.12-14 
Among the several associated factors of atherosclerosis, more attention has been 
given to the contribution of inflammation and its consequence in haemodialysis 
patients.15 The causes of inflammation in haemodialysis patients are multifactorial. 
The patients on dialysis have an increased production of TNF-α, IL-6, IL-10 and 
IL-12 due to the presence of inflammatory processes.16 Inflammatory reaction may 
originate from several sites including graft or fistula infections, bioincompatible 
dialysis membrane, dialysate, endotoxin exposure, back filtration, chronic 
infections, and malnutrition.17 Poor oral, dental and periodontal health in 
haemodialysis patients can be a source of inflammatory reactions.18, 19. 
Inflammation is closely related to protein–energy malnutrition in dialysis 
patients.20 Serum ferritin concentration and transferrin saturation(TSAT) ratio are 
among the two most commonly used markers of iron status in maintenance dialysis 
patients.21 The serum ferritin reflects storage iron, and absolute iron deficiency, 
according to the Kidney Disease Outcomes Quality Initiative(K/DOQI) guidelines, 
correlates with serum ferritin <100 ng/ml.22 The TSAT is the serum iron divided 
by the total iron-binding capacity (TIBC), which corresponds to circulating iron. 
The TIBC reflects transferrin, the protein to which virtually all iron in the blood is 
bound. The K/DOQI workgroups have determined that absolute iron deficiency, 
the absence or near absence of stainable iron in the bone marrow, correlates with 
TSAT <20% and that there is a risk for iron overload when the TSAT exceeds 
50%. It has been shown that patients on haemodialysis have worse oral condition 
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compared to general population, including increased prevalence for 
periodontitis.23-26  
The cornerstone of periodontal therapy is nonsurgical management which 
include scaling and root planing.27 One of the aims of Non-surgical periodontal 
therapy (NSPT) is to restore gingival health by completely removing elements that 
provoke gingival inflammation (which includes biofilm, calculus and endotoxins) 
from the tooth surface. NSPT have shown to reduce the number of subgingival 
microorganisms and also provide a shift in the composition of subgingival biofilm 
from one with higher number of gram negative anaerobes to one dominated by gram 
positive facultative bacteria compatible with health.1 NSPT have shown to improve 
the systemic inflammatory markers in patients with periodontitis.28-31 
Since there is higher prevalence of oral health disorders and also strong 
associations among chronic periodontitis, systemic inflammation and adverse 
outcomes in haemodialysis patients, more studies on periodontal therapeutic 
interventions are warranted. Therefore this study was designed to evaluate the effect 
of nonsurgical periodontal therapy (before and 3 months after) on clinical 
parameters[Bleeding on Probing (BOP), Plaque index (PI), Gingival index (GI), 
Probing pocket depth (PPD) and Clinical Attachment Level (CAL)], C-reactive 
protein and renal parameters (which include Serum ferritin, TSAT, serum albumin, 
serum creatinine, Haemoglobin, ESR, GFR) in haemodialysis patients with chronic 
periodontitis and compare the results with that of systemically healthy chronic 
periodontitis patients. 
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1. To evaluate oral health status, clinical parameters, vital signs, renal and 
haematological parameters in systemically healthy chronic periodontitis patients 
and chronic periodontitis patients with chronic kidney disease undergoing 
haemodialysis of varying duration. 
2. To assess the effect of non-surgical periodontal therapy on clinical parameters at 
baseline, 1 month and 3 months postoperatively. 
3. To assess the effect of nonsurgical periodontal therapy on renal and 
haematological parameters at baseline and 3 months postoperatively. 
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Kidney is composed of nearly one million anatomical and functional units 
which are called the nephrons.39 When a nephron is destroyed, it is unable to 
regenerate and therefore kidneys compensate by hypertrophy until half of the 
existing nephrons have been destroyed. Once this occurs, renal functional 
impairment starts to appear. Chronic kidney disease is characterized by a gradual 
reduction in the number of the functional nephrons which lead to progressive 
decrease in kidney function to renal failure. Proteinuria and hematuria are the 
most commonly used markers of kidney damage.40 There are several risk factors 
for chronic kidney disease which include age>60 years, diabetes, hypertension, 
obesity, macroalbuminuria, smoking, C-reactive protein, elevated total 
cholesterol.41 
 Chronic kidney disease is often complicated by multiple infections which 
is mostly due to impairments in both specific and nonspecific immune response.26 
Cardiovascular disease (CVD)- related events are the main reason for mortality in 
Chronic kidney disease patients.42 Systemic inflammation is considered as a non-
traditional risk factor for increased CVD events in such patients. When kidney 
function deteriorates, dialysis or renal transplantation is needed. Chronic kidney 
disease is defined as abnormalities of kidney structure or function, present for 
more than 3 months, with implications for health.43 The Kidney Disease: 
Improving Global Outcomes (KDIGO) organization developed clinical practice 
guidelines in 2012 which classified chronic kidney disease based on cause, GFR 
category and albuminuria category. Identifying the cause is emphasized due to its 
fundamental importance in predicting the outcome and guiding choice of cause 
specific treatment.  
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GFR categories have been mentioned below. 
G1: normal eGFR ≥ 90 mL/min per 1.73 m2 
G2: eGFR between 60 to 89 mL/min per 1.73 m2 
G3a: eGFR between 45-59 mL/min per 1.73 m2  
G3b: eGFR between 30-44 mL/min per 1.73 m2 
G 4: eGFR between 15 to 29 mL/min per 1.73 m2 
G5: eGFR< 15 mL/min per 1.73 m2 or end-stage renal disease (ESRD). 
Three albuminuria categories were proposed for simplification and initial 
assessment and prognostication. 
Albuminuria Albumin 
excretion rate 
Albumin-creatinine 
ratio Descriptor 
A1 <30 <30 Normal to mildly increased 
A2 30-300 30-300 moderately increased 
A3 >300 >300 severely increased 
 
End stage renal disease (ESRD) (GFR < 15 mL/min per 1.73 m2 is fatal 
without renal replacement, which can be provided by dialysis (haemodialysis or 
peritoneal dialysis) or renal transplantation.  
Periodontitis is a chronic inflammatory disease that leads to the destruction 
of periodontal tissue which is characterized by pocket formation, recession or both.40 
Severe periodontitis is  the sixth most common human disease which causes micro-
ulceration of the investing sulcular and pocket lining epithelium of the affected 
teeth.44 The systemic inflammatory response seen in periodontal disease has several 
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components which includes dissemination of periodontal pathogenic bacteria, their 
products and locally produced inflammatory mediators. Acute phase reactants are 
also found to be increased in periodontal disease.45 Therefore periodontal disease 
can in turn add to the chronic inflammation present in chronic kidney disease.  
Prevalence of Chronic Kidney Disease 
Kaze FF et al, 201546conducted a study to find the prevalence and 
determinants of CKD and albuminuria in urban and rural adults Cameroonians. This 
was a cross-sectional study of 6-month duration, conducted in the health district of 
Dschang (Western Region of Cameroon), using a multistage cluster sampling. All 
adults diagnosed with albuminuria (≥30 mg/g) and/or decreased estimated GFR (<60 
ml/min/1.73 m2) were re-examined three months later. Logistic regression models 
were used to relate baseline characteristics with prevalent CKD. Study included 439 
participants with a mean age of 47 ± 16.1 years; with 185 (42.1 %) being men and 
119 (27.1 %) being urban dwellers. There was a high prevalence of hypertension 
(25.5 %), diabetes (9.8 %), smoking (9.3 %), alcohol consumption (59.7 %), 
longstanding use of herbal medicine (90.9 %) and street medications (87.5 %), and 
overweight/obesity (53.3 %) which were predominant in rural area. The prevalence 
of CKD was 13.2 % overall, 14.1 % in rural and 10.9 % in urban participants. 
Equivalents figures for CKD stages G3-G4 [G3a(eGFR 45–59); G3b (eGFR 30–44); 
G4 (eGFR 15–29)] and albuminuria were 2.5 %, 1.6 % and 5.0 %; and 12.1 %, 14.1 
% and 6.7 % respectively. Existing hypertension and diabetes were associated with 
all outcomes. Elevated systolic blood pressure and the presence of hypertension and 
diabetes were the predictors of albuminuria and CKD while urban residence was 
associated with CKD stages G3-G4. They concluded that the prevalence of CKD 
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and albuminuria was high in this population, predominantly in rural area, and driven 
mostly by the commonest risk factors. 
Anupama YJ et al, 201447 conducted a study to find the prevalence of CKD 
in urban population near Shimoga, Karnataka and to study the risk factor profile. 
Door-to-door screening of 2091 people aged 18 and above was carried out. 
Demographic and anthropometric data were obtained, urine was analyzed for protein 
by dipstick and serum creatinine was measured in all participants. eGFR was 
estimated using the modification of diet in renal disease (MDRD) equation and 
Cockcroft‑Gault equation corrected to the body surface area (CG-BSA). The total 
number of subjects studied was 2091. Mean age was 39.88 ± 15.87 years of which 
45.57% were males. The prevalence of proteinuria was 2.8%. CKD was seen in 131 
(6.3%) subjects when GFR was estimated by MDRD equation. The prevalence of 
CKD was 16.54% by the CG-BSA method. There was a statistically significant 
relationship of CKD with gender, advancing age, abdominal obesity, smoking, 
presence of diabetes and hypertension. They concluded that the prevalence of CKD 
is higher compared to that from rural India and is comparable to from the urban 
Indian populations. The wide difference between the CKD prevalence between 
MDRD and CG‑BSA equations suggests the need for a better measure of kidney 
function applicable to Indian population.  
Singh KA et al, 201348 conducted a study to determine the prevalence and 
risk factors for CKD in India. This was a cross-sectional study which screened 6120 
Indian subjects from 13 academic and private medical centres all over India. The 
total cohort included in this analysis was 5588 subjects. The mean ± SD age of all 
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participants was 45.22 ± 15.2 years (range 18–98 years) and 55.1% of them were 
males and 44.9% were females. They also obtained personal and medical history 
data through a specifically designed questionnaire. Blood and urine samples were 
collected to find serum creatinine, plasma glucose and urine protein. Results of the 
study showed that the overall prevalence of CKD in the Screening and Early 
Evaluation of Kidney Disease Project(SEEK)-India cohort was 17.2% with a mean 
eGFR of 84.27 ± 76.46 versus 116.94 ± 44.65 mL/min/1.73 m2 in non-CKD group 
while 79.5% in the CKD group had proteinuria. Prevalence of CKD stages 1, 2, 3, 4 
and 5 was 7%, 4.3%, 4.3%, 0.8% and 0.8%, respectively. They also reported the 
most common risk factors and other characteristics among the subjects diagnosed 
with CKD as hypertension (64.5%), anemia (40.7%) and diabetes (31.6%). 
Ahmed I et al, 200649 conducted a study to estimate the prevalence of 
proteinuria in a rural adult population in Vellore district, Tamil Nadu. A convenient 
sample of 5043 adults was included. All individuals were tested for albuminuria by 
albumin dipstick examination in an untimed urine sample. Individuals who tested 
positive for albuminuria underwent a second dipstick examination after a gap of one 
week. Individuals with persistent albuminuria on the second dipstick examination 
underwent further evaluation which included medical history, physical examination, 
24 h urine protein estimation, total serum protein and albumin estimation. Ultrasound 
of the abdomen was done in patients with renal failure and renal biopsy was 
performed in selected patients. Of the total 5043 individuals screened, 63.1 per cent 
were females. Mean age of the study population was 50.94 ± 11.2 yr. First dipstick 
test identified 594 individuals positive for albuminuria. Repeat dipstick could be done 
in only 576, of whom 212 showed persistent albuminuria. Significant proteinuria was 
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detected in 24 individuals of the 208 who had 24 h urine protein measured. Of these 
24 patients, 3 were found to have chronic renal failure, 12 were presumed to have 
diabetic nephropathy clinically, one each had focal segmental glomerulosclerosis. The 
prevalence of proteinuria in this adult rural population was 0.47 per cent (0.30-
0.67%). The detection and treatment of chronic kidney disease in 24 individuals is 
bound to reduce the rate of decline of renal functions. Screening programme for 
proteinuria in different parts of country may be an effective measure to bring a decline 
in rate of progression of chronic kidney disease in general population. 
Etiological Factors in Chronic Kidney Disease 
Salman M et al, 201550conducted a study to evaluate the attributable causes 
of CKD in an adult population at a tertiary referral hospital. It was a retrospective 
study at Hospital Universiti Sains Malaysia (HUSM). This was an analysis based on 
medical records of adult patients at HUSM. Data regarding demographics, 
laboratory investigations, attributable causes and CKD stage were gathered. A total 
of 851 eligible cases were included. The patients’ mean age was 61.18 ± 13.37 
years. CKD stage V was found in 333 cases (39.1%) whereas stages IV, IIIb, IIIa, 
and II were seen in 240 (28.2%), 186 (21.9%), 74 (8.7%) and 18 (2.1%), 
respectively. The percentage of CKD stage V patients receiving renal replacement 
therapy was 15.6%. The foremost attributable causes of CKD were diabetic 
nephropathy (44.9%), hypertension (24.2%) and obstructive uropathy (9.2%). The 
difference in the prevalence of CKD due to Diabetic nephropathy, hypertension and 
glomerulonephritis between patients ≤50 and >50 years old was statistically 
significant. The study results suggested that DN and hypertension are the major 
attributable causes of CKD among patients at a Malaysian tertiary-care hospital.  
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Tuttle KR et al, 201451 reported in a consensus report that diabetes as a 
major cause for chronic kidney disease. The incidence and prevalence of diabetes 
mellitus have grown significantly throughout the world, due primarily to the 
increase in type 2 diabetes. This overall increase in the number of people with 
diabetes has had a major impact on development of diabetic kidney disease, one of 
the most frequent complications of both types of diabetes. Diabetic kidney disease is 
the leading cause of end-stage renal disease (ESRD), accounting for approximately 
50% of cases in the developed world. 
Tzanakaki E et al, 201452 examined the causes and complications of chronic 
kidney disease in patients on dialysis. The study population consisted of all 
prevalent patients on peritoneal dialysis (PD) or haemodialysis in the University 
Hospital of Heraklion, Crete. Causes of morbidity and hospitalizations were 
examined for all dialysis patients with at least one admission in the renal ward. 
Mortality was examined for a period of 33 months. An overall of 123 patients with 
diagnosed renal failure were studied. The data were collected through the patients 
medical records. Out of the 123 patients with ESRD who participated in the study, 
55.3% were men with a mean age of 65.3±15.2 years (range 16-85 years). The 
majority of patients (62.6%) were on HD, while 37.4% were on PD. Results showed 
that the major cause which seems to be responsible for the occurrence of chronic 
kidney disease as diabetic kidney disease (19,5%), followed by glomerulonephritis 
(18,7%). The major causes of hospitalization were infections (37.9%), including 
bacteraemia due to central catheter infection (40.4%), peritonitis in PD patients 
(19.1%), gastroenteritis (12.8%), respiratory tract infections (12.8%), urinary tract 
infections (6.4%) and other infections (such as cholangitis, skin infections etc) 8.5%. 
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Cardiac problems as a reason for hospitalization included pulmonary edema 
(57.1%), faint episodes, pulmonary embolism, decompensated heart failure and 
myocardial infarction (7.1% each). The study results concluded that the two major 
causes of hospitalization emerged in this study: catheter related infections and 
pulmonary edema. 
Nand N et al, 201253 conducted a study to evaluate the risk factors and their 
degree of reversibility in cases of acute and on chronic renal failure admitted to a 
tertiary care hospital over a period of one year. In this study 100 patients of acute-
on-chronic renal failure (rise in serum creatinine of 0.5 mg/dl, if baseline serum 
creatinine was < 3 mg/dl or rise of 1 mg/dl, if baseline was > 3 mg/dl within a one-
week period) were included and various reversible risk factors and the degree of 
reversibility of renal failure was determined. A thorough clinical evaluation and 
investigations of all patients was done and they were put on conservative 
management along with specific management of reversible factors and 
haemodialysis, wherever needed. The observations of various parameters were 
recorded at baseline and subsequently at 1 week and 2 week periods which included 
24-hour urine volume, blood urea, serum creatinine, and creatinine clearance. 
Reversibility of these parameters was then statistically analysed. To compare the 
degree of reversibility, the patients were divided into 4 groups at the time of 
admission depending upon their GFR; group 3 with GFR 30 - 59 ml/min, group 4 
with GFR 15 - 29 ml/min, group 5a with GFR 5 - 15 ml/min, and group 5b with 
GFR < 5 ml/min, respectively. Majority of patients were found to have more than 
one reversible risk factor. These were hyperuricaemia (89), electrolyte imbalance 
(51), infection/sepsis (47), accelerated hypertension (21), volume depletion (18), 
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urinary tract obstruction (16), and hypotension (7). A considerable degree of 
reversibility was detected, maximum being in volume depletion and urinary tract 
obstruction. Therefore it was concluded that patients presenting in a severe uremic 
state may not be suffering from ESRD and each patient should be investigated for 
the presence of reversible risk factors so that renal function can be restored and 
hence the need of renal replacement therapy can be delayed. 
Venkatachalam J et al, 201254 conducted a study to assess the risk factors of 
CKD. A community based cross sectional study was conducted among the 1200 
respondents, 20 years and above, residing in a coastal area of Villupuram district, over 
a period of 6 months using a pre-structured and validated questionnaire. The 
questionnaire included information on demographic characteristics, lifestyle habits, 
and awareness of CKD risk factors. Random blood sugar and spot urinary protein and 
sugar using urinalysis dipsticks were measured. Results showed that majority of the 
respondents were females (67.8%) with maximum belonging to the age group of 20- 
29yrs (23.8%), followed by 30-39yrs (22.8%). Most of them belonged to upper lower 
class (31.8%), followed by lower middle class (25.8%) of which 93.1% of the 
population were Muslims with 87.9% belonging to backward caste. The prevalence of 
CKD risk factors among the respondents were Proteinuria (12.5%), Glycosuria 
(8.4%), Hypertension (24.3%), Diabetes Mellitus (18%) and Obesity (44.4%). 
Fisher MA et al, 200855 conducted a study to investigate the role of 
periodontal disease and other non-traditional risk factors in patients with CKD by: 
(1) describing and quantifying the relationship between CKD and periodontal 
disease, along with the relationship between CKD and other non-traditional and 
traditional risk factors, in the Third National Health and Nutrition Examination 
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Survey (NHANES III); and (2) developing a multivariable model for the association 
between CKD and periodontal disease and other non-traditional risk factors, 
adjusting for traditional risk factors to identify risk factors independently associated 
with the presence of CKD. Data used in this study are: (1) responses to questions 
regarding age, race/ethnicity, gender, income, education, smoking, diabetes, and 
hypertension; (2) laboratory assays of serum cotinine, glycated hemoglobin, plasma 
glucose, serum CRP, serum creatinine, serum total cholesterol, serum HDL 
cholesterol, serum LDL cholesterol, urinary albumin, and urinary creatinine; and (3) 
clinical examination data for systolic and diastolic blood pressure, height, weight, 
and periodontal status. Chronic kidney disease prevalence was 3.6%; periodontal 
disease prevalence was 6.0%; and edentulism prevalence was 10.5%. Adults with 
periodontal disease and edentulous adults were twice as likely to have chronic 
kidney disease (adjusted odds ratio, 1.60; 95% confidence interval, 1.16 to 2.21; 
adjusted odds ratio, 1.85; 95% confidence interval, 1.34 to 2.56, respectively) after 
simultaneously adjusting for other traditional and non traditional risk factors. 
Middleton RJ et al, 200656 did a study to estimate the burden of CKD in 
patients with diabetes and to examine the ability of serum creatinine and 
albuminuria to detect clinically meaningful CKD compared with eGFR. All adults 
known to have diabetes in primary and secondary care in Salford, UK, alive with 
independent renal function on 1 January 2004 were included in this observational 
study (n=7596). Demographic and laboratory parameters were obtained from the 
Electronic Patient Record. eGFR was determined using the 4-variable modification 
of diet in renal disease (MDRD) formula. Creatinine and albuminuria were 
measured in the preceding 2 years in 82.3 and 55.2% of subjects, respectively. In 
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patients with CKD, normoalbuminuria was present in 48.8%, and serum creatinine 
was normal in 54.7%. An abnormal serum creatinine had a sensitivity and specificity 
of 45.3 and 100%, respectively, to identify CKD. The combination of abnormal 
creatinine and albuminuria had an improved performance but still failed to detect a 
large number with CKD (sensitivity 82.4%, specificity 75.4%). Serum creatinine 
failed to identify CKD more often in females (OR 8.22, CI 6.56–10.29). The study 
concluded that undiagnosed CKD is common in diabetes. Current screening 
strategies, based on creatinine or albuminuria, fail to identify a considerable number 
of subjects with CKD. Incorporating eGFR into screening for CKD would identify 
individuals earlier in the natural history of the disease and enable early effective 
treatment to delay progression of CKD. 
Treatments in Chronic Kidney Disease patients 
Molina P et al, 201357 conducted a study to evaluate whether vitamin D 
supplementation with daily cholecalciferol could reduce albuminuria in proteinuric 
chronic kidney disease (CKD) patients. This 6-month prospective, controlled, 
intervention study enrolled 101 non-dialysis CKD patients with albuminuria. 
Patients with low 25(OH) vitamin D [25(OH)D] and high parathyroid hormone 
(PTH) levels (n = 50; 49%) received oral cholecalciferol (666 IU/day), whereas 
those without hyperparathyroidism (n = 51; 51%), independent of their vitamin D 
status, did not receive any cholecalciferol, and were considered as the control group. 
Results showed that cholecalciferol administration led to a rise in mean 25(OH)D 
levels by 53.0 ± 41.6%. Urinary albumin-to creatinine ratio (uACR) decreased from 
(geometric mean with 95% confidence interval) 284 (189-425) to 167 mg/g (105-
266) at 6 months (P < 0.001) in the cholecalciferol group, and there was no change 
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in the control group. Reduction in a uACR was observed in the absence of 
significant changes in other factors, which could affect proteinuria, like weight, 
blood pressure (BP) levels or antihypertensive treatment. Six-month changes in 
25(OH)D levels were significantly and inversely associated with that in the uACR, 
after adjustment by age, sex, body mass index, BP, GFR and antiproteinuric 
treatment. The mean PTH decreased by −13.8 ± 20.3% only in treated patients, with 
a mild rise in phosphate and calcium–phosphate product. The study concluded that 
In addition to improving hyperparathyroidism, vitamin D supplementation with 
daily cholecalciferol had a beneficial effect in decreasing albuminuria with potential 
effects on delaying the progression of CKD. 
Al-Ageel NA et al, 201258 conducted a study to investigate current practice 
of anemia management in haemodialysis patients and to assess the appropriateness 
of anemia management by comparing observed practice to the Kidney Disease 
Outcomes Quality Initiative (KDOQI) guideline recommendations. Data on anemia 
parameters (Serum Ferritin and Transferrin saturation), comorbidities, 
erythropoiesis-stimulating agents (ESA) dosing and iron supplementation were 
collected. The data were collected for 7 months retrospectively from April to the end 
of May 2008 and prospectively from June to October 2008. Patients who were over 
18 years of age with ESRD undergoing haemodialysis were included. Patients were 
excluded if they have cancer or receiving chemotherapy or radiotherapy. Data were 
collected from 87 patients. Mean Haemoglobin value for those patients was 
11.16±0.97g/dL. Thirty-nine patients (45%) had mean Haemoglobin values between 
11.0 and 12.0 g/dL, the target range recommended by KDOQI guideline. The mean 
weekly prescribed dose of erythropoietin was 8099±5946 IU/Week (135±99 
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IU/kg/Week). Information on ferritin concentrations was available for 48 (55%) 
patients. The mean serum ferritin concentration for those patients was 693±420.5 
ng/mL. Fifty-two patients had transferrin saturation (TSAT) values recorded. The 
mean TSAT value was 38.5±19.7%. The study results concluded that there is an 
opportunity to improve anemia management in haemodialysis patients particularly 
thorough evaluation of causes of inadequate response rate and better monitoring and 
management of iron status. 
Link between Chronic Kidney Disease and Oral health status 
Ruokonen H et al, 201659 investigated whether oral disease inflammatory 
burden or different etiology (diabetes nephropathy vs. other etiologies) of CKD 
could be associated with mortality. This prospective cohort study comprised 144 
adults at the predialysis stage. Clinical oral and radiologic examination was made 
from 2000 to 2005. Patients were followed up until August 2015. Cause of death 
could be verified from 62 of 65 patients. Clinical health data were combined with 
mortality records obtained from the Finland national statistics database. Number of 
teeth, total dental index (TDI), and periodontal inflammatory burden index were 
calculated to describe degree of oral inflammation. Results showed that the primary 
causes of death were cardiovascular diseases, infection, and cancer. There was a 
statistically significant difference in survival between diabetic nephropathy (23.8%) 
and other patients with CKD (59.9%; log-rank test P <0.001). Also showed fewer 
teeth, higher age, and diabetes mellitus were statistically significant independent risk 
factors for death. Deceased patients had fewer teeth (P <0.001) and higher TDI (P 
<0.05). Study results concluded that risk of death was higher among patients with 
diabetic nephropathy. The deceased had fewer teeth and more oral infections.  
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Chhokra M et al, 201360 conducted a study to evaluate the periodontal 
health status of ESRD patients undergoing haemodialysis and establishing the 
underlying association between renal failure and periodontal disease. Eighty control 
and test subjects were included in the study, after matching age and sex. Creatinine 
and GFR were measured in each patient. Oral hygiene index- Simplified (OHI-S), 
GI, PI, CAL were recorded as periodontal parameters to assess the correlation 
between the subjects of the two groups. Further, the test group was divided into 
three sub-groups, on basis of duration, as less than 6 months, from 6 months to one 
year and more than one year. Results showed that statistical significant difference 
was observed for all periodontal parameters between the test and control group. 
However, difference amongst periodontal parameters on basis of duration of 
haemodialysis was seen between the subgroups of test subjects, it was not found to 
be statistically significant. They concluded that the severity of periodontal diseases 
in ESRD patients undergoing haemodialysis was majorly affected due to debilitating 
condition of the subjects. 
Brito F et al, 201219 in a cross-sectional study determined the extent and 
severity of periodontitis in chronic kidney disease patients undergoing the following 
three different treatment modalities: predialysis; continuous ambulatory peritoneal 
dialysis (CAPD); and HD; and then they compared the findings with those from 
systemically healthy individuals. Forty CAPD patients, 40 HD patients, 51 
predialysis patients and 67 healthy individuals were examined. The periodontal 
examination included probing pocket depth, clinical attachment loss, bleeding on 
probing and presence of plaque. Patients with at least four sites with clinical 
attachment loss ≥ 6 mm were considered to have severe chronic periodontitis, and 
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those with at least 30% of sites with clinical attachment loss ≥ 4 mm were 
considered to have generalized chronic periodontitis. Study results showed that 
predialysis and HD patients had significantly more sites with clinical attachment 
loss ≥ 6 mm than healthy individuals. The CAPD patients had similar periodontal 
condition to healthy subjects and there were significantly more cases of severe 
chronic periodontitis in predialysis and HD patients. They concluded that predialysis 
and HD are associated with a higher prevalence of severe periodontitis compared 
with healthy individuals and CAPD patients. 
Cengiz MI et al, 200961 conducted a study to investigate the dental and 
periodontal health status of patients on regular HD maintenance therapy, and the 
effect of duration of HD on oral status. Sixty-eight HD patients and 41 controls were 
examined. Decayed, Missing or Filled Teeth (DMFT index), PI, GI, PPD and loss of 
periodontal attachment (LPA) were examined. Except DMFT index, significant 
differences were found in the other index values between patients and controls. 
Dialysis duration significantly correlated not with DMFT but with the others. Also, 
DMFT values showed no significant differences between the five HD subgroups. 
For the PI, GI and PPD values, the first 5-year period revealed no significant 
variation, whereas the second 5-year period included significant increases. After 10 
years, a much more significant increase was observed. The LPA values did not show 
any significant differences between the HD subgroups, but after 10 years a 
significant progressive increase can be observed. They concluded that the dental and 
periodontal health is poor in HD patients and becomes worse with time on dialysis. 
Thus, oral health maintenance is of utmost importance in this patient group. 
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Chamani G et al, 200962 did a cross-sectional study on two groups of 
patients: one including 68 renal dialysis patients (test) and the other including 30 
healthy subjects (control). Half-mouth measurements of GI, PI, PPD, gingival 
recession (GR), CAL, BOP as well as DMFT index were recorded. The study results 
showed that the GI, BOP, PPD, CAL and GR were significantly greater among the 
test group as compared with the control group; however, the DMFT did not differ 
significantly among the groups. There was no relationship between the duration of 
the dialysis and the periodontal indices. They concluded that the patients with 
chronic renal failure have less favourable periodontal health than normal patients.   
Joseph R et al, 200963 assessed the prevalence of periodontal disease among 
a group of patients with renal disease and compared their periodontal status to that 
of healthy controls. 77 patients with different forms of renal disease and 77 healthy 
controls were examined for oral hygiene status, gingival inflammation, PPD and 
CAL. The subjects were grouped into three as no/mild, moderate and severe 
periodontitis. Results showed that all periodontal parameters were significantly 
elevated in the case group as compared to controls (p < 0.001). The prevalence and 
severity of periodontal disease was also significantly higher in the case group (p < 
0.001). This study provided evidence for a greater prevalence and severity of 
periodontal disease among patients with renal disease. 
Yoshihara A et al, 200764 conducted a study to investigate is a link exists 
between periodontal disease and chronic renal function in community dwelling 
elderly subjects. A total of 145 study subjects, all 77 years of age, participated in this 
study. A periodontal examination was carried out by trained dentists. Urine was 
collected over 24 hours, and blood was taken on the morning of the dental exam. 
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The volume of creatinine per 24 hours and volume of urine per 24 hours were used 
as urinary markers of kidney function; serum creatinine levels (Cre-S) were used as 
a blood marker of kidney function. Creatinine clearance per 24 hours was calculated 
as Cre-U/Cre-S. In addition, biochemical parameters of bone turnover were 
measured: urinary deoxypyridinoline (U-DPD) as a bone resorption marker and 
serum osteocalcin (S-OC) as a bone formation marker. Multiple regression analysis 
was used to evaluate the relationship between the percentage of periodontal sites 
with ≥6-mm clinical attachment level (% ≥6-mm CAL) and renal function, as well 
as the relationship between % ≥6-mm CAL and bone metabolism. The % ≥6-mm 
CAL was used as the dependent variable. Multiple regression analysis showed that 
creatinine clearance per 24 hours and S-OC were significantly associated with % ≥6-
mm CAL per person. The standardized coefficients were 0.26 (p = 0.015) and -0.27 
(p = 0.006), respectively. Study concluded that the % ≥6-mm CAL was significantly 
associated with renal function and bone metabolism markers. This study suggests 
that the increased incidence of chronic renal failure that occurs with age might 
increase the probability of severe periodontal disease in community-dwelling elderly 
subjects. 
Davidovich E et al, 200565 did a study to describe the oral condition of 
chronic renal failure and healthy subjects, and the relationship between oral 
variables, chronic renal failure (CRF) conditions, and their treatment. Four renal 
failure groups were included. They were: chronic renal disease (n=22); undergoing 
dialysis (n=22); after dialysis and transplant (n=21); and after transplant (n=32), and 
a healthy control (n=38) were examined. Caries, enamel hypoplasia, pulp 
obliteration, PI, gingival bleeding, recession, overgrowth and index, probing depths, 
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attachment loss, renal treatments and their relations with the oral variables were 
analysed. Results showed that the renal failure groups had higher GI and bleeding, 
probing depths, attachment loss, hypoplasia and obliteration and less caries, than the 
control. Plaque was higher in the dialysis and pre-dialysis groups. Overgrowth was 
evident after transplant. The pre-dialysis group showed lower GI than other renal 
groups. Dialysis duration and end-stage renal failure significantly correlated with 
gingivitis, probing depth, attachment loss and enamel hypoplasia. Immuran 
correlated positively with probing depth, gingival recession and attachment loss. 
Normiten and Nifedipine had positive correlations with gingival overgrowth. This 
study concluded that CRF patients are characterized by pulp obliteration, gingival 
and periodontal diseases and also that the duration of end stage renal failure and type 
of systemic treatment have a significant influence on the oral condition. 
Klassen JT et al, 200224 conducted a study to find the dental health status of 
dialysis patients. Completion of a questionnaire and a non-invasive oral examination 
was obtained from haemodialysis and peritoneal dialysis patients registered in the 
dialysis program at St. Paul’s Hospital in Saskatoon, Saskatchewan, as of March 1, 
1999. Information was also gathered from the medical chart. Medication history, 
history of diabetes, hypertension, and nondental prosthetic devices were also 
recorded. Of the 226 dialysis patients in central and northern Saskatchewan, 147 
were interviewed and examined. Of these, 94 (64%) were dentate, and the same 
number had been on dialysis for a mean of more than 2 years; about a third were 
diabetic, almost all were hypertensive and all had non-dental prosthetic devices or 
arteriovenous fistulae, or both. Sixty (64%) of the dentate patients were candidates 
for kidney transplantation. Most of the dentate patients reported brushing once or 
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more daily, but they flossed infrequently or never. Dental visits were infrequent, less 
than every 5 years in 59 (63%) of the dentate patients. Findings in the dentate group 
included increased tooth mobility, fractures, erosion, attrition, recession, gingivitis 
and a high plaque index. 
Effect of periodontal disease on renal disease parameters 
Grubbs V et al, 201666 investigated if periodontal disease brings about 
kidney function decline over time. In a longitudinal retrospective cohort of 761 
elderly men with preserved kidney function [estimated GFR > 60 mL/min/1.73 m2 
using a calibrated creatinine and cystatin C (eGFRcr-cys) equation] at baseline, 
multivariable Poisson’s regression was performed to examine the association of 
severe periodontal disease with incident CKD, defined as incident eGFRcr-cys<60 
mL/min/1.73 m2 and rapid (>5% annualized) eGFRcr-cys decline. At baseline, the 
mean age was 73.4 (SD 4.8) years, the median eGFRcr-cys was 82.4 mL/min/1.73 
m2, and 35.5 and 25.4% of participants had severe periodontal disease by European 
Workshop and CDC (Centre for Disease Control and Prevention)/AAP (American 
Academy of Periodontology) criteria, respectively. After a mean follow-up of 4.9 
years (SD 0.3), 56 (7.4%) participants had incident CKD. Severe periodontal disease 
was associated with a 2-fold greater rate of incident CKD after adjusting for 
confounders compared with not severe periodontal disease by European Workshop 
criteria but did not reach statistical significance by CDC/AAP criteria. They 
concluded that severe periodontal disease may be associated with incident clinically 
significant kidney function decline among a cohort of elderly men. 
Han SS et al, 201340 conducted a study to examine the correlations between 
periodontitis and both decreased GFR and urinary abnormalities, including 
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proteinuria and haematuria. Data on 15,729 Korean adults were obtained from the 
Korean National Health and Nutritional Examination Surveys IV and V. The CKD 
markers included a decreased estimated GFR (eGFR;<60 mL/min/1.73 m(2)), 
proteinuria, and haematuria. Odds ratios (ORs) and 95% confidence intervals were 
measured using stepwise multivariate logistic regression analyses for CKD markers 
based on the presence of periodontitis. Patients with periodontitis had greater 
unadjusted ORs for CKD markers compared to those without periodontitis, as 
follows: decreased eGFR, 4.07 (3.11-5.33); proteinuria, 2.12 (1.48-3.05); and 
haematuria, 1.25 (1.13-1.39, all P<0.001). Periodontitis was a significant predictor 
of decreased eGFR independent of all covariates. However, the effect of 
periodontitis on decreased eGFR seemed to be affected by hypertension and diabetes 
mellitus. Periodontitis was not an independent predictor of proteinuria; the 
significance disappeared after adjusting for hypertension and diabetes mellitus. 
Periodontitis was significantly correlated with haematuria, leading to similar ORs 
regardless of the adjustment for covariates. This study confirmed the correlation 
between periodontitis and CKD markers, including decreased eGFR, proteinuria, 
and haematuria in Korean adults. 
Kshirsagar AVet al, 200767 examined relationship between periodontitis 
and two measures of systemic inflammation, serum albumin and CRP were 
examined among patients who were receiving chronic outpatient haemodialysis. 
Adult patients at two locations, North Carolina and New York City were evaluated 
by dentist examiners. Multivariable logistic regression was used to determine the 
association of periodontitis with low serum albumin and with high CRP. Total 154 
patients completed the study. Study results showed that severe periodontitis was 
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associated with low serum albumin compared with individuals without severe 
periodontitis disease after adjustment for age, gender, race, diabetes, hypertension, 
body mass index, smoking, study site, total cholesterol, serum calcium, serum 
phosphorus, normalized protein catabolic rate. It also showed that there was no 
observed association of severe periodontitis with CRP. 
Bots CP et al, 200668 in a study aimed to compare the oral health status of 
chronic renal failure patients on renal replacement therapy with a matched reference 
population. This was a cross-sectional study with 42 dentate CRF patients - aged 25- 
52 years old and were matched with a reference group of 808 dentate subjects. The 
oral health was assessed using decayed missing filled (DMF) indices, simplified oral 
hygiene index and periodontal status. An oral health questionnaire was used to 
assess self-reported dental problems. Student t-tests and chi-square tests were 
performed to compare the chronic renal failure patients with the controls.  All index-
scores in the CRF patients were comparable with the controls except for number of 
teeth covered with calculus that was significantly higher (P < 0.05) in chronic renal 
failure patients (4.1 ± 2.6) than in controls (3.0 ± 2.9). The self-reported oral health 
questionnaire revealed a trend for increased temporomandibular complaints in 
chronic renal failure patients (16.7% vs 5.7% in controls; P ¼ 0.06) as well as bad 
taste (31.0% vs 6.8% in controls,P ¼ 0.08). They concluded that for most dental 
aspects, the oral health of chronic renal failure patients is comparable with controls. 
Effect of periodontal treatment on renal disease parameters 
Fang F et al, 201569 conducted a study to evaluate the effects of non-surgical 
periodontal therapy on the clinical response and systemic status of ESRD patients. 
Patients in the intervention group (n = 48) received nonsurgical periodontal therapy 
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and then a supragingival prophylaxis at the 3-month follow up, and those in the 
control group (n = 49) received no intervention throughout the study. At 6 weeks, 3 
months, and 6 months after therapy, clinical periodontal examinations were 
conducted and blood samples were taken to evaluate inflammatory, nutritional and 
lipid profiles. The results showed a significant improvement in clinical periodontal 
parameters in the intervention group. Compared to the control group, the 
intervention group had significantly lower high-sensitivity C-reactive protein at 3 
months and 6 months. Significant improvements were found in interleukin-6, 
ferritin, albumin, creatinine, blood urea nitrogen, and transferrin after therapy. The 
study results concluded that non-surgical periodontal therapy can effectively 
improve periodontal, circulating inflammatory and nutritional status in ESRD 
patients. Non-surgical periodontal therapy, as a relatively simple intervention, has 
beneficial systemic effects in ESRD patients. 
Chakraborty S et al, 201470 conducted a study to investigate differences in 
concentrations of serum ferritin in patients with and without periodontal disease 
before and after non-surgical periodontal therapy and correlate these values with 
clinical variables associated with periodontal disease. Forty-two individuals were 
included in this study, 20 with chronic periodontitis and 22 classified as 
periodontally healthy. Serum ferritin concentrations, haemoglobin levels, and 
periodontal parameters (PD, CAL, GI, BOP and PI) were recorded at baseline and 3 
months after non-surgical periodontal therapy. Results of the study showed that 
patients with CP showed higher concentrations of serum ferritin than periodontally 
healthy controls. Also a positive and significant correlation was observed between 
serum ferritin levels and the number of sites with PD ≥6 mm at baseline. Significant 
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reductions in serum ferritin levels were observed at the 3-month assessment after 
periodontal treatment, and the post-treatment serum ferritin values were comparable 
to those of controls (P >0.05). Furthermore, the post-treatment degree of change in 
the serum ferritin level was positively and significantly associated with 
improvement in PD. Study results concluded that serum ferritin levels are raised in 
patients with CP and decrease to control levels post-treatment. 
de Souza CM et al, 201471 investigated the impact of oral health indicators, 
chronic periodontitis and its treatment on survival rates in a group of patients 
undergoing haemodialysis. Clinically stable patients undergoing HD were referred 
for a dental examination. All patients were prospectively followed in the dialysis 
clinic, and all-cause mortality was recorded. Three groups of patients were analyzed: 
those who received CP treatment, those who did not, and patients without CP as a 
control group. A total of 122 patients were enrolled. Results showed that forty 
percent reported having rarely been evaluated by a dentist, and 59% had CP. There 
were 34 fatal events during a mean follow-up time of 64.1 ± 11.2 months. Oral 
factors associated with death in the univariate analysis were decreased frequency of 
dental visits; non-use of dental floss; increased decayed, missing, and filled teeth 
index; presence of CP; and absence of CP treatment. Patients with CP had a higher 
risk of death from all causes compared with patients without CP in the univariate 
analysis for untreated patients and to a lesser extent for treated patients. These 
significant differences were not maintained after adjustments for confounders in the 
multivariate model. The study results concluded that poor oral health, including CP, 
is a common finding in patients undergoing HD. 
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Siribamrungwong M et al, 201372 conducted a study to evaluate the 
association between chronic systemic inflammation and periodontal status and the 
effect of periodontal treatment in peritoneal dialysis patients. Clinical periodontal 
status was evaluated in 32 stable chronic peritoneal dialysis patients by PI and 
periodontal disease index. Hematologic, chemical, nutritional, and dialysis-related 
data as well as highly sensitive C-reactive protein were analyzed before and after 
periodontal treatment. At baseline, high sensitive CRP positively correlated with the 
clinical periodontal status (plaque index; r = 0.57, P < 0.01, periodontal disease 
index; r = 0.56, P < 0.01). After completion of periodontal therapy, clinical 
periodontal indexes were significantly lower and high sensitivity CRP significantly 
decreased from 2.93 to 2.21 mg/L. Moreover, blood urea nitrogen increased from 
47.33 to 51.8 mg/dL, reflecting nutritional status improvement. Erythropoietin 
dosage requirement decreased from 8000 to 6000 units/week while haemoglobin 
level was stable. Periodontitis is an important source of chronic systemic 
inflammation in peritoneal dialysis patients. The study results concluded that 
treatment of periodontal diseases can improve systemic inflammation, nutritional 
status and erythropoietin responsiveness in peritoneal dialysis patients. 
Wehmeyer MMH et al, 201373 conducted a study to determine the impact of 
treatment on clinical measures of periodontitis severity on dialysis patients; (2) to 
determine the impact of periodontal treatment on pre-specified laboratory 
parameters (serum albumin and interleukin-6); and (3) to assess recruitment and 
retention of patients. Dialysis patients with moderate or severe CP were selected. A 
total of 342 dialysis patients were approached for participation: 53 were randomized, 
with 26 participants assigned to immediate treatment and 27 to a control arm for 
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treatment after 6 months. Fifty one patients completed baseline appointments; 46 
were available for 3 month follow up and 45 were available for 6 month follow up 
examinations. Forty three participants completed all visits. At 3 months, there was a 
statistically significant improvement for the treatment group compared to the control 
group for 3 periodontal parameters: mean PD (p=0.008), extent PD ≥ 4 mm 
(p=0.02), and extent GI ≥1 (p=0.01). By 6 months, however, the difference between 
groups was no longer present for any variable except PD ≥ 4 mm (p=0.04). There 
was no significant difference between the groups for serum albumin or high-
sensitivity interleukin 6 at any time point, when adjusted for BMI, diabetic status, 
and plaque index. 
Yazdi FK et al, 201374 conducted a study to evaluate the impact of 
nonsurgical periodontal treatment on the serum levels of CRP in CKD patients on 
haemodialysis. A total of 77 CKD patients on haemodialysis were included in this 
study. At baseline, periodontal examination was assessed for all the patients, and 
chronic periodontitis was defined through CAL and PPD, according to the AAP. 
Nonsurgical periodontal treatment was performed and serum levels of CRP were 
evaluated at baseline and 8 weeks after periodontal treatment. Periodontal treatment 
resulted in significant reductions in CRP levels. The difference between pre and 
post-treatment CRP concentrations did not show any significant relationship with 
the severity of periodontitis. Study results concluded that nonsurgical periodontal 
treatment can effectively reduce the serum level of CRP in these patients. 
Ardalan M R et al, 201175 in a study assessed the severity and possible role 
of periodontitis in a group of patients with unknown primary glomerulonephritis. The 
study included ten patients with unknown primary glomerulonephritis, and who had a 
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renal biopsy with stable renal function and serum creatinine <1.6 mg/dL, were 
recruited. Severity of the periodontal disease was clinically measured with PI, GI and 
PPD. The dental treatments were aimed to eradicate the inflammatory/infectious 
diseases from the oral cavity by a wide variety of treatments, including oral hygiene 
instruction, nonsurgical or surgical periodontal therapy, systemic or topical 
medicaments, root canal therapy, and extraction, if needed. The patients were also put 
on angiotensin-converting enzyme inhibitor or angiotensin receptor blockers for 
controlling blood pressure and proteinuria. Six months following appropriate 
periodontal treatment, renal function, degree of proteinuria, and level of CRP were 
measured in each individual. The study results showed that the median urine protein 
excretion was lower following the periodontal therapy. Prior to the dental and/or 
periodontal therapies, the median PI, PD, and GI were 57.5%, 4.3, and 1.1, 
respectively. The majority of the patients had advanced periodontal disease. In four 
patients, +2/+3 CRP turned negative after periodontal treatment. This study revealed 
that a causative link might exist between periodontal disease and glomerulonephritis. 
Vilela EMet al, 201132 conducted a study to determine the impact of 
periodontal treatment on serum levels of prohepcidin (the prohormone of hepcidin) 
and systemic inflammation markers, as well as correlations among these markers, in 
patients with chronic periodontitis and chronic kidney disease who were not 
undergoing dialysis. This study consisted of 56 CP patients, 36 with chronic kidney 
disease and 20 without systemic diseases and with normal renal function (control 
group). The inflammatory markers ultrasensitive C-reactive protein, interleukin-6, 
and prohepcidin were evaluated before and 3 months after periodontal treatment. 
The following blood parameters were also found: complete hemogram (automated 
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Coulter STKS), serum iron (ferrozine), ferritin (electrochemiluminescence), and 
transferrin saturation index (Labtest ferrozine). The efficacy of periodontal treatment 
was confirmed by the improvement in clinical parameters of chronic periodontitis in 
the control and chronic kidney disease groups. Periodontal treatment resulted in 
significant reductions in ultrasensitive C-reactive protein, interleukin-6 and serum 
prohepcidin levels in both groups. There was also a reduction in prohepcidin after 
periodontal treatment was significantly and independently associated with 
interleukin-6 levels in the control group. They concluded that by inducing a decline 
in the systemic inflammatory response and a decrease in serum prohepcidin, 
successful periodontal treatment may represent an important means of ameliorating 
the inflammatory burden seen in patients with chronic kidney disease. 
Artese et al, 201076 conducted a study to investigate how predialysis CKD 
patients with periodontitis respond to non-surgical periodontal treatment. Twenty-
one predialysis patients (group 1) and 19 individuals without clinical evidence of 
kidney disease (group 2) with chronic periodontitis were subjected to non-surgical 
periodontal treatment with no antibiotics. Clinical periodontal and systemic 
parameters were evaluated at baseline and 3 months after treatment. Both groups 
showed significant and similar post-treatment improvements in all periodontal 
parameters examined. Most interestingly, periodontal treatment had a statistically 
significant positive effect on the glomerular filtration rate of each individual. Our 
results indicate that chronic periodontitis in predialysis kidney disease patients 
improved similarly in patients with chronic periodontitis and no history of CKD 
after receiving non-surgical periodontal therapy. This study demonstrates that CKD 
predialysis patients show a good response to non-surgical periodontal treatment. 
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Study design: 
This is a comparative interventional study for evaluating the level of C - 
reactive protein levels and iron indices in chronic periodontitis patients and in 
chronic kidney patients undergoing haemodialysis with chronic periodontitis before 
and after scaling and root planing procedure. 
Study settings: 
The chronic periodontitis patients for the study were selected from the 
Outpatient of Department of Periodontics and Oral Implantology, Sree Mookambika 
Institute of Dental Sciences, Kulasekharam and chronic kidney disease patients 
undergoing haemodialysis where referred from Department of Nephrology, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam for oral prophylaxis. 
Study duration 
The study duration was of 6 months, which lasted from July 2016 to 
December 2016. 
Informed consent and Ethical considerations 
The study protocol was approved by the Institutional Research Committee of 
Sree Mookambika Institute of Dental Sciences (Ref No. 18/06/2015, Annexure-1) 
and also by the Institutional Human Ethics Committee of Sree Mookambika Institute 
of Medical Sciences, Kulasekharam (Ref No: SMIMS/IHEC/2-15/A/05, Annexure-
2) and was registered under the Clinical Trial Registry of India. The Clinical trial 
registration number is REF/2016/01/010407 
Study protocol was explained to patient and the information on the nature 
and potential benefit of their participation in the study was also explained 
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(Annexure-3). Informed consent was obtained from all subjects after screening 
(Annexure-4). 
Sample size calculation: 
Sample size was calculated based on the previous study by Vilela EM et al, 
201132 
In which it was reported that the C- reactive protein values as follows. 
Chronic periodontitis patients with CKD = 6.18+5.39(mg/L) 
Chronic periodontitis patients without CKD (controls) = 3.04+3.82(mg/L)  
The sample size n = 
(

	
)
∆
 
Where z (1- a /2)   is the alpha error whose value for significance level of 10%, 
is 1.645 and  z(1- b )   is the beta error or power of the study whose value power of  
80% is  0.8416. 
∆  =   
			
.   =    
.		.	
	.   = 0.822  
 Alpha error at 5% significance level = 1.645 
Beta error (power) at 80 % = 0.8416 
Sample size    n= (.		.)
	
.  =   
	.	
		.   =18.3 rounded off to 20 
for each group 
 The number of participants required in each intervention group is 20 for a 
Significance level of 10% and power of 80% 
Total sample size = 3x 20 = 60 
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The selected patients were assigned into 3 groups; each group consisting of 
20 patients. 
Group I -  Twenty Chronic kidney disease patients undergoing haemodialysis 
for less than a year with chronic periodontitis 
Group II -  Twenty Chronic kidney disease patients undergoing haemodialysis 
for more than a year with chronic periodontitis 
Group III -  Twenty systemically healthy chronic periodontitis patients 
Inclusion criteria:  
Group I: Twenty Chronic kidney disease patients undergoing haemodialysis for less 
than a year with chronic periodontitis 
i. Patients with chronic periodontitis was diagnosed when there was two or 
more interproximal sites with CAL ≥4 mm, not on the same tooth, or two 
or more interproximal sites with PPD ≥5 mm, not on the same tooth (Page 
and Eke, 2007)33 
ii.  Patients with ≥ 20 teeth 
iii. Patients with bleeding on probing. 
iv. Patients undergoing haemodialysis for atleast 3months and less than a year. 
Group II: Twenty Chronic kidney disease patients undergoing haemodialysis for 
more than a year with chronic periodontitis 
i. Patients with chronic periodontitis was diagnosed when there was two or 
more interproximal sites with CAL ≥4 mm, not on the same tooth, or two 
or more interproximal sites with PPD ≥5 mm, not on the same tooth.33 
ii. Patients with ≥ 20 teeth 
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iii. Patients with bleeding on probing.  
iv. Patients undergoing haemodialysis for more than a year. 
Group III: Twenty systemically healthy chronic periodontitis patients 
i. Patients with chronic periodontitis was diagnosed when there was two or 
more interproximal sites with CAL ≥4 mm, not on the same tooth, or two 
or more interproximal sites with PPD ≥5 mm, not on the same tooth.33 
ii.  Patients with ≥ 20 teeth 
iii. Patients with bleeding on probing. 
Exclusion criteria:  
1. Edentulous patients 
2. Smokers, alcoholics, pregnant women and lactating mothers. 
3. Patients who had undergone periodontal treatment in the past 6 months 
Clinical parameters 
Periodontal examination was conducted in the Department of Periodontics, 
Sree Mookambika Institute of Dental Sciences, Kulasekharam.  
The following clinical parameters were assessed using William’s graduated 
periodontal probe. Clinical parameters were assessed at six sites of all teeth 
(mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual and distolingual) at 
baseline, 4 weeks and after 3 months following non surgical periodontal therapy. 
1. Plaque index (PI)34 
2. Gingival index (GI)35 
3. Bleeding on Probing(BOP) 36 
4. Probing pocket depth(PPD) 
5. Clinical attachment Level(CAL) 
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Renal and haematological parameters 
1. Serum C-reactive Proteins(CRP) 
2. Total Iron Binding Capacity(TIBC) 
3. Serum Iron 
4. Transferrin saturation ratio(TSAT) 
5. Serum Ferritin 
6. Haemoglobin(Hb)  
7. Erythrocyte Sedimentation Rate(ESR) 
8. Serum albumin 
9. Serum creatinine 
10. Glomerular Filtration rate(GFR) 
Armamentarium 
The collection of blood and non surgical periodontal therapy were performed 
with the following requirements.(Colour Plate-1) 
1. Mouth mirror 
2. Explorer 
3. William’s periodontal probe. 
4. Gracey Area specific curettes. 
5. 23 gauge 5ml disposable plastic syringe. 
6. 25 gauge 2ml disposable plastic syringe. 
7. Clot activator tube.  
8. KEMI C-48 centrifuge.  
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Procedure 
After the patients were included in the study, blood samples were collected 
and sent to the Central laboratory of Sree Mookambika Institute of Medical Science 
for the estimation of renal and haematological parameters. For Group I and group II 
systemic antibiotics [2g amoxicillin or 600mg Clindamycin (if patient had an allergy 
to amoxicillin)] were administered 1 hour prior to the periodontal therapy 
appointment only, in order to minimize the effect of any transient bacteremia on the 
patient’s dialysis catheter.37,38 Antibiotics were not administered at any other 
appointment. PI, GI, BOP, PPD and CAL were recorded from each patient of the 
three groups. The clinical, renal and haematological parameters recorded at the 
baseline were given as T0. After baseline evaluation (T0), all the patients received 
nonsurgical periodontal therapy, which includes oral hygiene instructions, 
supragingival and subgingival scaling and root planing under local anesthesia using 
ultrasonic instruments and hand instruments as needed. (Annexure-5) 
Patients were recalled after 1 month and 3 months during which clinical 
parameters were recorded as T1 and clinical, renal & haematological parameters 
recorded as T2 respectively (Annexure-6).  
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The study design flowchart is given below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic Periodontitis patients (CP)(n=60) 
Group I (n=20) 
CKD patients undergoing 
haemodialysis< 1 year 
Group III (n=20) 
Systemically healthy CP 
Group II (n=20) 
CKD patients undergoing 
haemodialysis> 1 year 
Baseline Evaluation 
(T0) 
Clinical Parameters 
PI, GI, BOP, PPD, CAL 
Renal and 
Haematological 
parameters 
CRP, Serum iron, TIBC, 
TSAT, Serum Ferritin, 
Hb, ESR, Serum albumin, 
serum creatinine, GFR 
Baseline Evaluation 
(T0) 
Clinical Parameters 
PI, GI, BOP, PPD, CAL 
Renal and 
Haematological 
parameters 
CRP, Serum iron, TIBC, 
TSAT, Serum Ferritin, 
Hb, ESR, Serum albumin, 
serum creatinine, GFR 
 
Baseline Evaluation (T0) 
Clinical Parameters 
PI, GI, BOP, PPD, CAL 
Renal and 
Haematological 
parameters 
CRP, Serum iron, TIBC, 
TSAT, Serum Ferritin, 
Hb, ESR, Serum albumin, 
serum creatinine, GFR 
 
Scaling and root 
planing under antibiotic 
prophylaxis 
Scaling and root 
planing under antibiotic 
prophylaxis 
Scaling and root 
planing 
1 month postoperative (T1) 
Clinical parameters (PI, GI, 
BOP, PPD, CAL) 
1 month 
postoperative(T1)  
Clinical parameters (PI, 
GI, BOP, PPD, CAL) 
1 month postoperative(T1) 
Clinical parameters (PI, 
GI, BOP, PPD, CAL) 
 
3 months 
postoperative(T2) 
Clinical parameters 
Renal and haematological 
parameters 
3 months 
postoperative(T2) 
Clinical parameters 
Renal and haematological 
parameters 
3 months 
postoperative(T2) 
Clinical parameters 
Renal and haematological 
parameters 
Screening of Outpatients from Department of Periodontics 
Informed consent obtained 
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Sample Preparation 
Under sterile conditions from each patient of three groups, 5ml of venous 
blood sample was collected at baseline and three months after the non surgical 
periodontal therapy from the ante-cubital fossa by venipuncture using 23 gauge 
needle and 5ml syringe (Colour Plate-2). Collected blood is transferred to a clot 
activator tube and placed for 30 minutes at room temperature and then centrifuged at 
3000 rpm for 10min (Colour Plate-3). The serum obtained is then used for the 
estimation of renal and haematological parameters (Colour Plate-4). 
Method 
The evaluation of the renal and haematological parameters were done at the 
Central Lab of Sree Mookambika Institute of Medical Sciences, Kulasekharam.  
1. Serum C reactive proteins levels: Analysed using Beckman Coulter Analyzer 
(Colour Plate-5)[Tris buffer (pH 7.5), (Reagents-Sodium Chloride, Polyethylene 
glycol 6000, anti-CRP Antibodies(Colour Plate-6)] by Turbidimetric method.  
2. Serum iron, TIBC, creatinine and albumin: Analysed using Beckman Coulter 
AU 480 Fully Automated Analyzer(Colour Plate-7)  
3. TSAT is measured as a percentage and is a medical laboratory value. It is the 
ratio of serum iron and total iron binding capacity.  
4. The normal mean GFR for young adults is approximately 120-
130mL/min/1.73m2.9GFR calculated using the Modification of Diet in Renal 
Disease (MDRD) study equation. 
GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female). 
Scr is serum creatinine. 
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5. Serum Ferritin analysed using Beckman Coulter Access 2 Immunoassay System 
by Chemiluminescent detection method.(Colour Plate-8, 9, 10) 
6. Hemoglobin and ESR  investigations executed by automated haematology 
analyser and 5-part differential counter in Beckman Coulter Ac. T 5 Diff CP & 
Mindray BC 5300 5 diff (Method used is colorimetric method for determining 
Hb and Westergren method for ESR)(Colour Plate-11) 
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Colour Plate -5. Autoanalyzer to measure C-reactive protein 
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Colour Plate -7. Beckman Coulter AU 480 Fully automated analyzer for 
estimation of Serum iron, TIBC, serum creatinine and albumin 
 
 
Colour Plate -8. Samples placed in the sample holder for estimation of serum ferritin 
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Colour Plate -9. Reagents loaded in the analyzer 
 
 
 
Colour Plate -10. Beckman Coulter Access 2  
Immunoassay System for estimation of serum ferritin 
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Colour Plate -11. Beckman Coulter fully automated analyzer for haemoglobin 
estimation and ESR 
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The purpose of the study was to compare the effect of non-surgical 
periodontal therapy on periodontal parameters, renal and haematological parameters 
in systemically healthy chronic periodontitis patients and in chronic periodontitis 
patients with chronic kidney disease undergoing haemodialysis of varying duration. 
The study consisted on 3 groups with 20 patients in each group. 
Group I : Chronic periodontitis patients with chronic kidney disease undergoing 
haemodialysis for less than a year 
Group II : Chronic periodontitis patients with chronic kidney disease undergoing 
haemodialysis for more than a year 
Group III :  Systemically healthy chronic periodontitis patients. 
Baseline data for PI, GI, BOP, PPD and CAL was recorded for all the 
patients in each group. Before periodontal treatment blood samples were collected 
and sent to the laboratory for estimation of renal and haematological parameters. 
After non-surgical periodontal therapy, at the end of 4 weeks and 3 months, patients 
were recalled and periodontal parameters were recorded. Renal and haematological 
parameters were recorded at the end of 3 months only.  
Statistical Analysis 
The data was analyzed by Statistical Package for Social Sciences (SPSS 
16.0) version. The data was tested for normality. One way ANOVA (post hoc) 
followed by Dunnet t test was applied to find the statistical significance between the 
groups. Paired t test and Chi square test was applied to find the statistical 
significance between the T0 and T2 time within the groups. P value less than 0.05 
was considered statistically significant at 95% confidence interval.  
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Table-1: Comparison of demographic and clinical observations between the 
groups   
Observations Group-I Group-II Group-III p value 
Age (years) 
(MEAN±SD) 51.15±9.66 49.90±1.20 41.35±8.79*
,# 0.04 
Gender     
Male 16 17 7*,# 0.04 
Female 4 3 13*,# 0.03 
BMI (kg/m2) 
(MEAN±SD) 22.25±2.73 23.23±1.48 23.00±2.60 1.34 
SBP (mmHg) 
(MEAN±SD) 135.80±3.66 136.50±3.03 118.40±6.03*
,#
 0.04 
DBP (mmHg) 
(MEAN±SD) 93.80±4.25 93.30±3.06 80.40±4.08*
,#
 0.04 
Number of teeth 
present (MEAN±SD) 27.35±3.74 27.55±3.83 28.15±3.16 2.67 
 
(*p<0.05 significant compared Group-I with other groups, #P<0.05 significant 
compared Group-II with other groups) 
 
Table 1 shows the demographic and the vital signs of the patients at baseline. 
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Table-2:  Comparison of mean periodontal parameters at T0 between the 
groups  
Groups Plaque Index (MEAN±SD) 
Gingival index 
(MEAN±SD) 
Bleeding on 
probing(%) 
(MEAN±SD) 
Probing pocket 
depth(mm) 
(MEAN±SD) 
Clinical 
attachment 
level(mm) 
(MEAN±SD) 
Group 
I 1.78±0.50 1.58±0.28 34.16±1.16 2.94±0.32 3.38±0.59 
Group 
II 1.74±2.65 1.58±0.29 34.37±1.27 2.98±0.43 3.35±7.66 
Group 
III 1.79±0.34 1.71±0.35 45.09±1.43*
,#
 3.10±0.52*,# 3.37±0.62 
p value 2.90 2.89 0.05 0.05 3.45 
(*p<0.05 significant compared with Group-I, #P<0.05 significant compared 
with) 
 
Table 2 shows the comparison of mean periodontal parameters at baseline 
(T0) between the groups. This shows that there was statistically significant 
difference(p<0.05) with respect to bleeding on probing and probing pocket depth in 
chronic periodontitis group when compared to the haemodialysis groups whereas in 
respect to PI, GI and CAL difference between the three groups at baseline was not 
statistically significant.  
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Table-3: Comparison of mean periodontal parameters at T1 between the 
groups  
Groups Plaque Index  (MEAN±SD) 
Gingival index 
(MEAN±SD) 
Bleeding on 
probing (%) 
(MEAN±SD) 
Probing pocket 
depth (mm) 
(MEAN±SD) 
Clinical 
attachment 
level (mm) 
(MEAN±SD) 
Group 
I 1.33±0.35 1.35±0.12 26.97±6.91 2.78±0.33 3.22±0.57 
Group 
II 1.37±0.22 1.37±0.12 27.06±1.01 2.82±0.43 3.16±7.23 
Group 
III 1.47±0.22 1.44±0.20 
33.63±1.43*,
#
 
3.00±0.45 3.26±0.57 
p value 1.67 1.98 0.05 2.12 1.45 
(*p<0.05 significant compared with Group-I, #P<0.05 significant compared with 
Group-II) 
 
When comparing the mean periodontal parameters at T1 (one month 
postoperative) it was shown that there was no statistically significant difference in 
PI, GI, PPD and CAL in all the three groups, except the BOP (p<0.05) in group III 
when compared to Group I and Group II.(Table 3)  
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Table-4: Comparison of mean periodontal parameters at T2 between the 
groups  
Groups Plaque Index (MEAN±SD) 
Gingival index 
(MEAN±SD) 
Bleeding on 
probing(%) 
(MEAN±SD) 
Probing pocket 
depth(mm) 
(MEAN±SD) 
Clinical 
attachment 
level(mm) 
(MEAN±SD) 
Group 
I 1.34±0.30 1.30±0.08 22.03±5.43 2.69±0.27 3.12±0.49 
Group 
II 1.41±0.28 1.32±0.13 23.30±9.11 2.78±0.47 3.07±0.75 
Group 
III 1.35±0.19 1.31±0.14 23.20±5.96 2.87±0.39 3.10±0.50 
p  
value 1.45 1.93 2.12 2.94 1.98 
(p>0.05 no significant difference compared between the groups) 
 
Comparison of the mean periodontal parameters at T2 (3 months 
postoperative) between the groups showed that there was no statistically significant 
difference(Table 4).  
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Table-5: Comparison of mean periodontal parameters of Group-I at different 
time periods  
Time 
Group I 
Plaque Index 
(MEAN±SD) 
Gingival 
index 
(MEAN±SD) 
Bleeding on 
probing (%) 
(MEAN±SD) 
Probing 
pocket depth 
(mm) 
(MEAN±SD) 
Clinical 
attachment 
level (mm) 
(MEAN±SD) 
T0 1.78±0.50 1.58±0.28 34.16±1.16 2.94±0.32 3.38±0.59 
T1 1.33±0.35* 1.35±0.12 26.97±6.91* 2.78±0.33 3.22±0.57 
T2 1.34±0.30* 1.30±0.08 22.03±5.43*,# 2.69±0.27 3.12±0.49 
p 
value 0.05 1.56 0.04 1.34 2.19 
(*p<0.05 significant compared with T0, #p<0.05 significant compared with T1) 
 
When comparing the periodontal parameters of group I at different time, it 
was shown that all the periodontal parameters improved from T0 to T2, but the 
decrease was statistically significant (p<0.05) only in relation to PI and 
BOP.(Table 5). 
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Table-6: Comparison of mean periodontal parameters of Group-II at different 
time periods  
Time 
Group II 
Plaque Index 
(MEAN±SD) 
Gingival index 
(MEAN±SD) 
Bleeding on 
probing (%) 
(MEAN±SD) 
Probing 
pocket depth 
(mm) 
(MEAN±SD) 
Clinical 
attachment level 
(mm)(MEAN±SD) 
T0 1.74±2.65 1.58±0.29 34.37±1.27 2.98±0.43 3.35±7.66 
T1 1.37±0.22* 1.37±0.12 27.06±1.01* 2.82±0.43 3.16±7.23 
T2 1.41±0.28* 1.32±0.13 23.30±9.11*,# 2.78±0.47 3.07±0.75 
p 
value 0.05 2.67 0.04 1.89 1.23 
(*p<0.05 significant compared with T0 with others, #p<0.05 significant 
compared with T1) 
 
When comparing the mean periodontal parameters of group II at different 
time periods, it was shown that plaque index decreased significantly at T1 when 
compared to T0, but again at T2 it was shown that PI score increased when 
compared to T1 but was not statistically significant. With regard to other parameters, 
it was shown that GI, PPD and CAL improved from baseline to T2, but significant 
difference was seen only in relation to BOP at both time periods. 
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Table-7: Comparison of mean periodontal parameters of Group-III at different 
time periods  
Time 
Group III 
Plaque Index 
(MEAN±SD) 
Gingival index 
(MEAN±SD) 
Bleeding on 
probing(%) 
(MEAN±SD) 
Probing pocket 
depth(mm) 
(MEAN±SD) 
Clinical 
attachment 
level(mm) 
(MEAN±SD) 
T0 1.79±0.34 1.71±0.35 45.09±1.43 3.10±0.52 3.37±0.62 
T1 1.47±0.22* 1.44±0.20 33.63±1.43* 3.00±0.45 3.26±0.57 
T2 1.35±0.19* 1.31±0.14*,# 23.20±5.96*,# 2.87±0.39*,# 3.10±0.50*,# 
p 
value 0.05 0.04 0.04 0.05 0.05 
(*p<0.05 significant compared T0 with others, #p<0.05 significant compared T1 
with others) 
 
Table 7 shows the comparison of mean periodontal parameters of group III at 
different time periods. It was shown that PI and BOP decreased significantly at T1 
and T2 when compared with T0 and improvement in GI, PPD and CAL was 
significant at T2 only when compared to T0. When compared with T1 statistically 
significant improvement was seen in relation to BOP, GI, PPD and CAL at T2. 
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Table-8: Comparison of mean CRP, Iron, TIBC and TSAT values between the 
groups at T0 time 
Groups CRP(mg/L) (MEAN±SD) 
Iron(µg/dl) 
(MEAN±SD) 
TIBC (µg/dl) 
(MEAN±SD) 
TSAT(%) 
(MEAN±SD) 
Group-I 8.06±6.04 38.49±8.94 182.91±38.01 22.02±7.85 
Group-II 8.37±6.93 54.31±1.55* 185.05±48.66 29.99±7.77* 
Group-III 2.50±0.60*,# 68.08±1.23*,# 241.22±63.08*,# 29.76±8.34* 
p value 0.02 0.001 0.02 0.04 
(*p<0.05 significant compared with Group-I, #p<0.05 significant compared with 
Group-II) 
 
Comparison of the mean CRP, serum iron, TIBC and TSAT values between 
the groups at T0 showed that serum iron and TSAT improved significantly in group 
II and group III whereas CRP and TIBC improved significantly in group III only 
when compared to group I. CRP decreased, serum iron and TIBC increased 
significantly in group III when compared to group I.(Table 8). 
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Table-9: Comparison of mean CRP, Iron, TIBC and TSAT values between the 
groups at T2 time 
Groups CRP (mg/L) (MEAN±SD) 
Iron (µg/dl) 
(MEAN±SD) 
TIBC (µg/dl) 
(MEAN±SD) 
TSAT (%) 
(MEAN±SD) 
Group-I 7.08±5.36 46.77±11.90 204.00±39.99 24.04±8.47 
Group-II 7.63±6.12 54.61±16.20* 182.47±47.30* 30.60±7.27* 
Group-III 1.09±0.65*,# 70.50±13.98*,# 233.41±63.60*,# 31.89±8.68*,# 
p value 0.02 0.002 0.04 0.03 
(*p<0.05 significant compared with Group-I, #p<0.05 significant compared with 
Group-II) 
 
Comparison of mean CRP, serum iron, TIBC and TSAT between the groups 
at T2 showed that the serum iron and TSAT increased statistically significantly in 
group II and group III when compared to group I. TIBC decreased statistically 
significantly in group II at T2, but increased statistically significantly at T2 in group 
III. It was also shown that CRP, Iron, TIBC and TSAT improved significantly in 
group III when compared to group II(Table 9). 
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Table-10: Comparison of mean CRP, Iron, TIBC and TSAT values of Group-I 
between T0 and T2 
Time 
Group-I 
CRP (mg/L) 
(MEAN±SD) 
Iron (µg/dl) 
(MEAN±SD) 
TIBC (µg/dl) 
(MEAN±SD) 
TSAT (%) 
(MEAN±SD) 
T0 8.06±6.04 38.49±8.94 182.91±38.01 22.02±7.85 
T2 7.08±5.36* 46.77±11.90* 204.00±39.99* 24.04±8.47* 
p value 0.04 0.04 0.001 0.05 
(*p<0.05 significant compared with T0) 
 
Comparison of mean CRP, iron, TIBC and TSAT values of Group I at T0 
and T2 showed that CRP decreased, serum iron, TIBC and TSAT increased at T2 
from that of T0 and the difference was statistically significant.(Table 10). 
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Table-11: Comparison of mean CRP, Iron, TIBC and TSAT values of Group-II 
between T0 and T2 
Time 
Group-I 
CRP(mg/L)  
(MEAN±SD) 
Iron(µg/dl)  
(MEAN±SD) 
TIBC (µg/dl) 
(MEAN±SD) 
TSAT (%) 
(MEAN±SD) 
T0 8.37±6.93 54.31±1.55 185.05±48.66 29.99±7.77 
T2 7.63±6.12 54.61±16.20 182.47±47.30* 30.60±7.27* 
p value 1.56 1.78 0.05 0.05 
(*p<0.05 significant compared with T0) 
 
Comparison of mean CRP, serum iron, TIBC and TSAT of group II at T0 
and T2 showed that serum CRP decreased, serum iron increased, TIBC decreased 
and TSAT increased at T2 from that of T0, but the difference was statistically 
significant with respect to TIBC and TSAT alone.(Table 11) 
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Table-12: Comparison of mean CRP, Iron, TIBC and TSAT values of Group-
III between T0 and T2 
Time 
Group-III 
CRP (mg/L) 
(MEAN±SD) 
Iron (µg/dl) 
(MEAN±SD) 
TIBC (µg/dl) 
(MEAN±SD) 
TSAT (%) 
(MEAN±SD) 
T0 2.50±0.60 68.08±1.23 241.22±63.08 29.76±8.34 
T2 1.09±0.65* 70.50±13.98* 233.41±63.60* 31.89±8.68* 
p value 0.03 0.05 0.04 0.05 
(*p<0.05 significant compared with T0) 
 
When mean CRP, serum iron, TIBC and TSAT of group III was compared at 
T0 and T2, it was shown that all these parameters improved significantly at 
T2.(Table 12). 
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Table-13: Comparison of mean renal and haematological parameters between 
the groups at T0 time  
Groups 
Ferritin 
(ng/mL) 
(MEAN±SD) 
Hb (gm/dL) 
(MEAN±SD) 
ESR (mm/Hr) 
(MEAN±SD) 
Albumin 
(gm/dL) 
(MEAN±SD) 
Group-I 458.78±2.55 9.04±1.58 66.40±19.49 3.92±0.31 
Group-II 427.80±3.28* 8.71±1.68* 56.05±19.73* 4.11±0.36* 
Group-III 51.41±2.11*,# 11.71±1.35*,# 19.70±8.26*,# 4.06±0.19 
p value 0.001 0.04 0.001 0.05 
(*p<0.05 significant compared with Group-I, #p<0.05 significant compared with 
Group-II) 
 
 
Comparison of serum ferritin, Hb, ESR and serum albumin between the 
groups at T0 showed that statistically significant difference was seen in relation to 
serum ferritin, Hb and ESR in group II and Group III compared with group I and 
also statistically significant difference was seen in serum albumin with respect to 
group II only when compared to group I. at baseline, it was also shown that there 
was statistically significant difference in serum ferritin, Hb and ESR in group III 
when compared to group II.(Table 13) 
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Table-14: Comparison of mean renal and haematological parameters between 
the groups at T2 time  
Groups 
Ferritin 
(ng/mL) 
(MEAN±SD) 
Hb (gm/dL) 
(MEAN±SD) 
ESR(mm/Hr)  
(MEAN±SD) 
Albumin 
(gm/dL) 
(MEAN±SD) 
Group-I 500.34±2.96 9.54±1.95 59.45±19.56 3.98±0.21 
Group-II 469.81±3.22* 8.76±1.65* 53.80±23.41* 4.04±0.25 
Group-III 47.36±2.23*,# 12.04±1.04*,# 17.45±6.41*,# 4.06±0.22 
p value 0.001 0.04 0.002 1.67 
(*p<0.05 significant compared with Group-I, #p<0.05 significant compared with 
Group-II) 
 
Table 14 shows that statistically significant difference in serum ferritin, Hb 
and ESR was present at T2 in group II and Group III when compared to Group I and 
also statistically significant difference was seen in group III at T2 when compared to 
that of Group II.(Table 14) 
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Table-15: Comparison of mean renal and haematological parameters within 
the Group-I at different time periods  
Groups 
Group-I 
Ferritin 
(ng/mL) 
(MEAN±SD) 
Hb(gm/dL)  
(MEAN±SD) 
ESR (mm/Hr) 
(MEAN±SD) 
Albumin 
(gm/dL) 
(MEAN±SD) 
T0 458.78±2.55 9.04±1.58 66.40±19.49 3.92±0.31 
T2 500.34±2.96* 9.54±1.95 59.45±19.56* 3.98±0.21 
p value 0.001 1.89 0.03 2.45 
(*p<0.05 significant compared with T0) 
 
Within Group I at T0 and T2, it was shown that serum ferritin increased and 
ESR decreased significantly at T2 when compared to baseline. It was also noted that 
Hb and serum albumin increased at T2 from that of baseline, eventhough it was not 
statistically significant.(Table 15). 
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Table-16: Comparison of mean renal and haematological parameters within 
the Group-II at different time periods  
Groups 
Group-II 
Ferritin 
(ng/mL) 
(MEAN±SD) 
Hb (gm/dL) 
(MEAN±SD) 
ESR(mm/Hr)  
(MEAN±SD) 
Albumin 
(gm/dL) 
(MEAN±SD) 
T0 427.80±3.28 8.71±1.68 56.05±19.73 4.11±0.36 
T2 469.81±3.22* 8.76±1.65 53.80±23.41* 4.04±0.25 
p value 0.003 1.45 0.05 1.19 
(*p<0.05 significant compared with T0) 
 
Comparison of serum ferritin, Hb, ESR and serum albumin within group II at 
different time periods showed that serum ferritin increased and ESR decreased at T2 
from that of baseline and the difference was statistically significant (Table 16). 
 
 
 
 
 
 
 
 
 
 
 
Results and Observation 
 
   Page 59 
 
Table-17: Comparison of mean renal and haematological parameters within 
the Group-III at different time periods  
Groups 
Group-III 
Ferritin 
(ng/mL) 
(MEAN±SD) 
Hb (gm/dL) 
(MEAN±SD) 
ESR (mm/Hr)  
(MEAN±SD) 
Albumin 
(gm/dL) 
(MEAN±SD) 
T0 51.41±2.11 11.71±1.35 19.70±8.26 4.06±0.19 
T2 47.36±2.23* 12.04±1.04 17.45±6.41* 4.06±0.22 
p value 0.04 2.89 0.05 1.56 
(*p<0.05 significant compared with T0) 
 
Table 17 shows the comparison of serum ferritin, Hb, ESR and serum 
albumin in group III at baseline and T2, it was shown that serum ferritin and ESR 
decreased at T2 from that of T0 and the difference was statistically significant. 
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Table-18: Comparison of mean creatinine and GFR values between the groups 
at T0 and T2 time  
Groups Creatinine at T0 time (MEAN±SD) 
Creatinine at T2 
time 
(MEAN±SD) 
GFR at T0 
time 
(MEAN±SD) 
GFR at T2 
time 
(MEAN±SD) 
Group I 8.71±1.98 8.46±2.31 7.40±1.98 7.70±2.69 
Group II 6.69±2.68* 8.17±3.95 11.20±6.32* 9.45±5.94* 
Group III 0.79±0.11*,# 0.74±0.10*,# 99.55±1.47*,# 105.40±1.46*,# 
p value 0.001 0.001 0.001 0.001 
(*p<0.05 significant compared with Group-I, #p<0.05 significant compared with 
Group-II) 
 
Table 18 shows mean serum creatinine and GFR between the groups at T0 
and T2. It showed that statistically significant difference was seen in serum 
creatinine and GFR in group II and Group III when compared to Group I at T0 and 
also statistically significant difference was seen in group III compared to group II in 
terms of serum creatinine and GFR at T0. Table 18 also shows that statistically 
significant difference in GFR was present in group II when compared to Group I and 
statistically significant difference was seen in group III with respect to serum 
creatinine and GFR compared to Group I and Group II at T2.  
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Table-19: Comparison of mean creatinine and GFR values within the groups at 
different time periods  
Time 
Group-I Group-II Group-III 
Creatinine 
(MEAN±SD) 
GFR (mL/ 
min/1.73m2) 
(MEAN±SD) 
Creatinine 
(MEAN±SD) 
GFR(mL/ 
min/1.73m2) 
(MEAN±SD) 
Creatinine 
(MEAN±SD) 
GFR (mL/ 
min/1.73m2) 
(MEAN±SD) 
T0 8.71±1.98 7.40±1.98 6.69±2.68 11.20±6.32 0.79±0.11 99.55±1.47 
T2 8.46±2.31 7.70±2.69 8.17±3.95 9.45±5.94 0.74±0.10 105.40±1.46* 
p 
value 1.67 1.45 0.06 0.06 2.45 0.05 
(*p<0.05 significant compared with T0) 
 
Table 19 shows the comparison of serum creatinine and GFR within the 
group at T0 and T2. In Group I it was noted that serum creatinine decreased and 
GFR increased at T2 from that of baseline, but it was not statistically significant.  
In Group II Table 19 shows that serum creatinine and GFR decreased at T2 
from that of baseline, but that was also not statistically significant. 
In Group III it was shown that serum creatinine decreased and GFR 
increased at T2 from that of baseline, but the increase in GFR alone was statistically 
significant. 
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Graph-1. Comparison of mean Plaque Index values of different groups 
 
Graph-2: Comparison of mean Gingival Index between the groups 
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Graph-3: Comparison of mean Bleeding on Probing values of different groups 
Graph-4: Comparison of mean Probing Pocket Depth between the groups 
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Graph-5: Comparison of mean Clinical Attachment Level between the groups 
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Chronic kidney disease occurs due to a slow and progressive decline of 
kidney function. It happens gradually over a period of weeks, months or years as the 
kidneys slowly stop working, leading to End stage renal disease (ESRD).77 Both 
chronic kidney disease as well as renal replacement therapy that includes 
haemodialysis, peritoneal dialysis, or renal transplantation can affect periodontal 
tissue.74 Periodontal disease is an inflammatory disease that affects the supporting 
tissues of the teeth mainly due to the interaction between specific bacterial species 
and the host immune response in disease susceptible individuals.78 Local destruction 
that occurs in periodontitis can in turn lead to the production of inflammatory 
mediators such as C-reactive protein (CRP), Interleukin-6, Interleukin-1, TNF-α and 
Prostaglandin-E2. Periodontitis has been reported to be associated with increased 
systemic inflammatory burden even in end stage renal disease patients on 
haemodialysis maintenance therapy which in turn may exacerbate the existing 
metabolic disorder which include hyperglycemia, hypertension and dyslipidemia in 
these patients.69, 79, 80 These low grade systemic inflammation, such as due to 
periodontitis has been reported to increase the risk for cardiovascular events.59 
However, periodontal diseases are treatable and can be considered as a modifiable 
risk factor.78 Treating periodontal disease may decrease the proinflammatory state in 
this population. It may also improve the oral discomfort and improve the nutritional 
status.81 In a study it was reported that following periodontal therapy the mean CRP 
level and erythrocyte sedimentation rate decreased and haemoglobin level increased 
in haemodialysis patients, suggesting a decrease in inflammatory state.82 Therefore, 
non surgical periodontal therapy was found to eliminate periodontal infection as 
well as improve systemic status, both of which are involved in the progression of 
ESRD.70, 83   
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Plaque index (PI) provides a quick and simple method of monitoring a 
patient’s ability to control plaque from the tooth surface. Our study results showed 
that the Plaque Index score was reduced in the initial one month postoperative(T1) 
after which at 3 months postoperative(T2) there was a slight increase in PI in the 
haemodialysis groups (Group I and Group II)(Graph 1). This shows the poor 
compliance to the oral hygiene instructions given to the haemodialysis group. This is 
in accordance with the study conducted by Wehmeyer et al, 201373 in which it was 
shown that there was decrease in the PI at 3 months post operative after which at 6 
months there was an increase in haemodialysis group, which showed poor 
maintenance in haemodialysis patients. Fang et al, 201569 also showed similar results 
in which after initial periodontal therapy the periodontal parameters were found to 
be reduced and then during the follow up it was found to be increased in the 
haemodialysis group which is in support to the results of our study. But the decrease 
in PI score was statistically significant in both Group I and Group II from baseline to 
3 months postoperative.  
GI is a method of recording the clinical severity of gingival inflammation. GI 
was also found to be reduced from baseline to 3 months post-treatment, but was not 
statistically significant in Group I and II (Graph 2). BOP is a simple and reliable 
indicator of gingival inflammation, which was found to be reduced in Group I and 
Group III significantly from baseline to 3 months post-treatment (Graph 3). Probing 
pocket depth (PPD) and Clinical attachment level (CAL) was also found to be 
reduced, though not statistically significant from baseline to T2 in Group 1 and 
Group II (Graph 4 and Graph 5). 
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 In the systemically healthy chronic periodontitis group, all the clinical 
parameters (PI, GI, BOP, PPD and CAL) decreased significantly at 3 months 
postoperatively (Table 7) which is similar to the results of the study conducted by 
Radafshar et al. 2010,81 Graziani et al. 2010,83   Artese et al. 2010,76 Fang et al. 
201569. All these studies showed a significant reduction in the clinical parameters 
postoperatively in systemically healthy chronic periodontitis patients. This shows 
good compliance to the oral hygiene instruction given in Group III when compared 
to that of Group I and Group II. 
C- reactive protein level in our study results showed that postoperatively 
there was statistically significant reduction in Group I and Group III(8.06±6.04 
(mg/L) to 7.08±5.36 mg/L,p= 0.04 and 2.50±0.60 mg/L  to 2.09±0.65 mg/L, p=0.03, 
respectively) (Table 8 and Table 9) whereas the reduction in the CRP level in Group 
II was not statistically significant, this shows that the inflammation in Group II 
(Chronic kidney disease patients undergoing haemodialysis for more than a year) 
was more severe than that of Group I (Chronic kidney disease patients undergoing 
haemodialysis for less than a year). Also at baseline, it was shown that CRP level 
was more in Group II than that of Group I (8.06±6.04 mg/L and 8.37±6.93 mg/L, 
respectively) (Table 8), which might be due to the severity in inflammation in group 
II than in Group I. This is in accordance with that study by Yazdi et al, 2013 which 
showed reduction in CRP level in maintenance haemodialysis patients after 2 
months of periodontal therapy (9.369±11.25mg/L to 5.628±4.79 mg/L).74 Study by 
Fang et al, 2015 also showed that compared to the periodontitis patients who did not 
receive any treatment, CRP values decreased in periodontitis patients who were 
under maintenance haemodialysis. One of the best predictor of cardiac and all-cause 
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mortality in ESRD patients on haemodialysis are CRP values.84 Inflammation 
arising from infections associated with destructive periodontal diseases appears to 
contribute to elevated values of systemic CRP. Since destructive periodontal disease 
is a treatable condition, its management can bring about a decrease in CRP values 
and the associated risk of atherosclerotic complications in ESRD patients 
undergoing haemodialysis.78 
Transferrin saturation is calculated as a percentage of serum iron and total 
iron binding capacity (TIBC), which corresponds to the circulating iron. The TIBC 
reflects transferrin, which is the protein to which all iron in the blood is bound. Due 
to inflammatory stimulation, the iron that is in the reticuloendothelial storage gets 
locked up and is not released to transferrin. As a result of which, TSAT is low, 
despite a normal or elevated ferritin.85 There will be decrease in the transferrin 
saturation which leads to decrease in erythropoiesis and contributes to the 
development of anemia of chronic diseases.86 In our study it was shown that 3 
months after periodontal treatment, transferrin saturation was found to increase in all 
three group significantly (p<0.05) (Table 8 and Table 9). This was similar to the 
results in the study by Vilele EM et al.32   
Serum ferritin is an acute phase reactant and has been reported to be increased 
in inflammation, autoimmune disease, chronic infection and liver diseases.70 In our 
study it was shown that serum ferritin was found to be significantly more in 
haemodialysis group when compared to the serum ferritin level in chronic 
periodontitis at baseline. In group I and group II, serum ferritin level was found to 
be increased at 3 months postoperatively (458.78±2.55 ng/mL to 500.34±2.96 
ng/mL and 427.80±3.28 ng/mL to 469.81±3.22 ng/mL, respectively) (Table 15 and 
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Table 16), whereas in systemically healthy chronic periodontitis group, serum 
ferritin reduced 3 months postoperatively. Study conducted by Chakraborty et al, 
201470 showed that after 3 months of nonsurgical periodontal therapy, serum ferritin 
was found to be reduced in systemically healthy chronic periodontitis patients which 
was similar to that of our study. During acute phase response, proinflammatory 
cytokines interleukin 1 beta and tumour necrosis factor alpha (TNF-α) increase the 
synthesis of various subunits of ferritin. Inflammation induced hyperferritinemia can 
block the iron mobility and hence be harmful under chronic inflammation by leading 
to refractory anemia, such as in chronic kidney disease or other chronic disease 
states.87 This can be the reason for the increase in serum ferritin in haemodialysis 
group inspite of improvement in the clinical parameters.  
Lower haemoglobin levels were seen at baseline in all the three groups, 
which might be due to due to proinflammatory cytokines, which act as mediators in 
suppressing erythropoiesis from bone marrow.70 The present study also showed that 
at 3 months post-treatment, there was an increase in the Haemoglobin level which 
was not statistically significant (p>0.05). It also showed a statistically significant 
reduction in the ESR rate in all the three groups 3 months post-operatively (p<0.05) 
(Table 13 and Table 14). ESR is considered as a valuable parameter for 
inflammatory process. The results regarding haemoglobin and ESR was also similar 
to that of study conducted by Musalaiah et al,31 Agarwal N et al.88 Improvement in 
ESR postoperatively was due to a reduction of the periodontal inflammation and the 
inflammatory markers.89 Non surgical periodontal treatment can improve the anemic 
status of patients on chronic periodontitis and thereby bring about improvement in 
the haematological parameters in turn.  
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Albumin is a negative acute phase reactant, which tends to be lower in case 
of inflammation.90 In our study it was shown that the serum albumin level was found 
to increase 3 months postoperatively in Group I (3.92±0.31 gm/dL to 3.98±0.21 
gm/dL, not statistically significant, p=2.45) and was found to decrease in the Group 
II after 3 months postoperatively(4.11±0.36 gm/dL to 4.04±0.25 gm/dL, not 
statistically significant, p=1.19) whereas it was almost at the same level in the Group 
III patients from baseline to T2 (4.06±0.19 gm/dL to 4.06±0.22 gm/dL) (Table 13 
and Table 14). In our study there was no much statistically significant difference in 
the serum albumin level in the groups between baseline and 3 months 
postoperatively. Our results are similar to the study by Wehmeyer et al.73 In their 
study they reported that the intensive periodontal treatment was not associated with 
an improvement in serum albumin level at either 3 or 6 months of follow up. Two 
important factors that regulate albumin synthesis are nutritional intake and illness.91 
Albumin levels have been reported to decrease inflammatory disorders and other 
illness. Factors regulating serum albumin are similar in patients with and without 
chronic kidney disease. This might be the reason, that serum albumin levels did not 
vary much in chronic periodontitis group and chronic kidney disease patients 
undergoing haemodialysis.  
Serum creatinine level decreased in Group I and group III, but in group II 
there was an increase in the serum creatinine in Group II from baseline to 3 months 
post periodontal treatment, but the difference was not statistically significant. With 
regard to GFR also, in Group I and Group III increased (7.40±1.98 mL/min/1.73m2 
to 7.70±2.69 mL/min/1.73m2, p=1.45 and 99.55±1.47mL/min/1.73m2 to 
105.40±1.46 mL/min/1.73m2 *, p=0.05* respectively), whereas decreased in Group 
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II (11.20±6.32 mL/min/1.73m2 to 9.45±5.94 mL/min/1.73m2, p=0.06) (Table 19). 
Artese et al, 2010 in his study reported that serum creatinine decreased and GFR rate 
increased in predialytic patients and also in systemically healthy chronic 
periodontitis patients.76 Graziani et al, 2010 in a study have shown an improvement 
in the GFR in chronic periodontitis patients after nonsurgical periodontal therapy.83 
In Chronic kidney disease, there is steady and continuous decrease in renal clearance 
or GFR, which leads to gathering of creatinine, urea and other substances in the 
blood.77 Inflammation in periodontal disease can cause increase in inflammatory 
markers, which can lead to progression of kidney disease and a further increase in 
inflammatory markers. Therefore a reduction of inflammation and the consequent 
improvement of endothelial function associated with periodontal therapy can in turn 
have an impact on the kidney microcirculation with a subsequent more effective 
filtration.83 
Demmer RT et al.,92 de Freitas et al.,93 Ioannidou E et al.,94  in a systematic 
review reported that there was reduction in systemic CRP following periodontal 
treatment in periodontitis patients. Chambrone L et al. in a systematic review also 
gave quite a consistent evidence to support the positive association between 
periodontitis and chronic kidney disease, as well as the positive effect on periodontal 
therapy on estimated GFR.95 
The present study has limitations that need to be clearly discussed which 
include use of antibiotics in chronic kidney disease patients undergoing 
haemodialysis before non-surgical periodontal therapy which could have affected 
the clinical, renal and haematological parameters. Another limitation includes 
relatively small sample size and short duration of follow up (3 months) of the study. 
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The objective of the present study was to evaluate the effect of nonsurgical 
periodontal therapy on clinical parameters (at baseline, 1 month and 3 months), renal 
[C-reactive protein (CRP), Transferrin Saturation (TSAT), Serum ferritin] 
haematological parameters (haemoglobin, Erythrocyte Sedimentation Rate) (at 
baseline and 3 months) in systemically healthy periodontitis patients and chronic 
kidney disease patients undergoing haemodialysis of varying duration. The clinical 
parameters (Plaque index, Gingival index, Bleeding on Probing, Probing Pocket 
Depth, Clinical Attachment Level) was found to be reduced in both the groups after 
periodontal therapy. It was also noted that CRP levels decreased and TSAT 
increased in all the three groups, serum ferritin was found to increase in chronic 
kidney disease patients undergoing haemodialysis, where as decreased in 
systemically healthy chronic periodontitis patients. Thus we conclude that 
nonsurgical periodontal therapy can contribute to improvement in acute phase 
reactants like CRP and iron indices in systemically healthy chronic periodontitis 
patients and in chronic kidney disease patients undergoing haemodialysis. Further 
studies with larger sample size and longer duration of follow up are required to 
validate the observations of the present study. 
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PATIENT INFORMATION SHEET 
 
 
 
 
 
 
 
 
 
1. Name of the Principal Investigator:  
 
 
 
 
2. Name of the Guide:      
 
 
3. Name of the Co-Guide: 
 
 
 
4. Institute : Sree Mookambika Institute of Dental Sciences, 
     Kulasekharam 
5. Title of the study: ‘Effect of nonsurgical periodontal therapy on C-reactive 
protein and iron indices in haemodialysis patients with chronic periodontitis’ .
  
Dear Volunteers, 
We welcome you and thank you for your keen interest in 
participation in this research project. Before you participate in this study, it is 
important for you to understand why this research is being carried out. This 
form will provide you all the relevant details of this research. It will explain the 
nature, the purpose, the benefits, the risks, the discomforts, the precautions and 
the information about how this project will be carried out. It is important that 
you read and understand the contents of the form carefully. This form may 
contain certain scientific terms and hence, if you have any doubts or if you want 
more information, you are free to ask the study personnel or the contact person 
mentioned below before you give your consent and also at any time during the 
entire course of the project. 
Dr. Sheethel.Menon.V 
Post graduate student,  
Department of Periodontics 
SMIDS,Kulasekaram 629161 
Cell: 9445678206 
sheethel.menon@gmail.com 
 
Dr Arun Sadasivan, MDS 
Professor, 
Department of Periodontics 
SMIDS, Kulasekharam 629161 
Cell: 9847246961 
sadasivan_arun@hotmail.com 
Dr. Elizabeth Koshi, MDS 
Head of the Department, 
Department of Periodontics, 
SMIDS, Kulasekharam 629161 
Cell: 09447154335 
elizabethkoshi_dr@yahoo.com 
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6. Background information:  
From the review of several scientific publications from 2009 to 2014  
7. Aims and Objectives: 
The aim of the study is to evaluate the effect of scaling and root planing on 
changes in the C-reactive protein and iron indices in chronic periodontitis patients 
and in renal patients undergoing haemodialysis with chronic periodontitis 
8. Scientific justification of the study: 
Non-Surgical Periodontal therapy can bring about decrease in the bacterial 
load and improve the periodontal status which can bring about decrease in the CRP 
level and also increase the level of serum iron, serum ferritin and TIBC in 
haemodialysis patients with chronic periodontitis and decreases periodontal 
destruction. Periodontal Therapy is able to reduce acute-phase proteins levels and 
systemic inflammatory markers, which are involved in the progression of renal 
disease.13Thus periodontal therapy should also be able to exert beneficial effects on 
the function of the kidney. 
9. Procedure for the study: 
• Once you are enrolled into the study a roll number will be implemented to represent 
the name.   
• When you visit the clinic for periodontal examination, under sterile condition 
5ml blood samples will be collected using a syringe and 23 gauge needle and 
sent to the laboratory for estimation of CRP level and the level of serum iron, 
serum ferritin and TIBC. 
• Then you will be undergoing periodontal examination that involves the 
evaluation of gums as well as the amount of plaque present on the teeth. 
• Then you will be undergoing scaling and root planing(Cleaning of teeth). 
• You will be recalled after 1 month and periodontal status will be re-evaluated 
and again 5 mL of blood samples will be collected for the above mentioned 
analysis. 
10. Expected risks for the participants: 
Pain, ecchymosis are expected very rarely. 
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11. Expected benefits of research for the participants: 
There is no direct benefit to you. This study will enhance our knowledge 
aboutthe effect of nonsurgical periodontal therapy onthe level of CRP level and 
serum iron, serum ferritin and TIBC in chronic periodontitis patients and in renal 
patients undergoing haemodialysis with chronic periodontitis 
 12. Maintenance of confidentiality: 
• You have the right to confidentiality regarding the privacy of your medical 
information(Personal details, results of physical examinations, 
investigations, and your medical history). 
• By signing this document, you will be allowing the research team 
investigators, other study Personnel, sponsors, institutional ethics committee 
and any person or agency required by law to view your data, if required.  
• The results of clinical tests and therapy performed as part of this research 
may be included in your medical record.  
• The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
13. Why have I been chosen to be in this study? 
You were selected from a pool of patients in outpatient Department of 
Periodontics, Sree Mookambika Institute of Dental Sciences, Kulasekharam and 
Department of Nephrology, Sree Mookambika Institute of Medical Sciences, 
Kulasekharam. You will be informed of this study and will be invited to participate. You 
have been invited to this study because you fulfill our inclusion criteria by being a 
systemically healthy subject between the age of 30-65yrs. No invasive procedure is done 
that harm your health and it helps in diagnosis and will be helpful for the society.  
14.How many people will be in the study? Sixty individuals 
15. Agreement of compensation to the participants (In case of a 
study related injury): Patient will be taken care in case of complication and 
medical treatment will be provided in the institution at the expense of the principle 
investigator. 
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16. Anticipated prorated payment, if any, to the participant(s) of the 
study: 
Nil 
17. Can I withdraw from the study at any time during the study 
period? 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving any 
reasons. 
18. If there is any new findings/information, would I be informed?  
Yes     
19. Expected duration of the participant’s participation in the 
study:  
Six Months 
20. Any other pertinent information: No other information 
21. Whom do I contact for further information? For further 
information, free feel to contact: 
 
 
 
 
 
 
Place:  
Date:        
Signature of the participant                      Signature of Principal Investigator 
 
Dr. Sheethel Menon.V 
Post graduate student,  
Department of Periodontics, 
 SMIDS,  
 Kulasekaram 629161 
Ph: 9445678206 
sheethel.menon@gmail.com 
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k½X ]{Xw þ `mKw þ 1 
]T\hpambn klIcn¡p¶ hyànIfpsS Adnhntebv¡v 
 
{]nbs¸« k¶² tkhI³ / tkhI, 
 R§Ä \n§sf kzmKXw sN¿p¶p.  AtXmsSm¸w Cu ]T\hpambn klIcn¡m\pÅ 
k¶²XtbmSv \µn tcJs¸Sp¯p¶p.  \n§Ä Cu ]T\¯nÂ ]s¦Sp¡p¶Xn\p ap³]v Cu ]T\w  
F´n\mWv \S¯s¸Sp¶Xv F¶v Andtb−Xp−v. AXn\mÂ Cu t^md¯nÂ  KthjW ]T\¯nsâ 
hnhc§fpw aäpw  hniZambn tcJs¸Sp¯nbncn¡p¶p.  Cu ]T\¯nsâ coXn, Dt±iw, {]tbmP\w, 
A]ISkm²yX, t¢iw, ap³IcpXÂ, F§s\ Cu ]T\w  ap³t]m«p sIm−pt]mIp¶p F¶n§s\  FÃm 
hnhc§fpw  t^md¯nÂ  tcJs¸Sp¯nbncn¡p¶p.  kZbw Cu  hnhc§Ä  hmbn¨p a\Ênem¡phm³  
A`yÀ°n¡p¶p.  Cu hnhc§fnÂ imkv{X]camb ]Z§Ä DÅXn\mÂ  kwib\nhmcW¯n\p {][m\ 
]T\IÀ¯mhnt\mtSm Xmsg tcJs¸Sp¯nbncn¡p¶ hyànItfmtSm t^mdw H¸nSp¶Xn\p ap³t]m 
AsÃ¦nÂ Cu ]T\¯nsâ Imemh[n Xocp¶Xphtctbm kao]n¡mhp¶XmWv.  
 
1. apJy KthjI³ :  tUm. ioXÄ tat\m³.hn 
    t]mÌp{KmPpthäv 
    Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv   
      {io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kv, 
    IpetiJcw þ 629 161. 
    t^m¬: 9445678206 
     
2. {][m\ amÀ¤ZÀin : tUm.Acp¬ kZminh³ 
s{]m^kÀ 
Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv  
{io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv, 
IpetiJcw. 
t^m¬: 9847246961 
     
3. kl amÀ¤ZÀin : tUm. Fenks_¯v tImin 
slUv Hm^v Zn Un¸mÀ«vsaâv, 
Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv  
{io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv, 
IpetiJcw. 
t^m¬: 9447154335 
 
tUm. _o\m D®nIrjvW³ 
 Atkmkntbäv s{]m^kÀ   
    P\dÂ saUnkn³ hn`mKw,    
    {io aqImw_nI C³Ìnäyq«v Hm^v saUn¡Â kb³kkv. 
      IpetiJcw 
Mob: 9947777615 
     Email: beena.unnikrishnan@gmail.com 
 
4. C³Ìnäyq«v  : {io. aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv 
    ]S\new, IpetiJcw, 
    I\ymIpamcn þ 629 161. 
    Xangv\mSv.  
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5. ]T\¯nsâ ioÀjIw  :  
kvsIbvenwKv & dq«v t¹\nwKv  NnInÕbv¡v ap³]pw tijhpw s]cntUmssâänkv  tcmKnIfnepw,  
lotamUbmenknkv sN¿p¶ s]cntUmssâänkvtcmKnIfnepw D−mIp¶    kn-- -dnbmIv«nhv t{]m«o\nepw  
Ccp¼v  kqNnIIÄ - -epw hcp¶ hyXymkw.  
6. ]Ým¯e hnhcw ? 
 2009 apXÂ 2014 hscbpÅ imkv{Xob {]kn²oIcW§fnÂ \n¶pw tiJcn¨ hnhcW§Ä.  
 
7. e£y§fpw Dt±i§fpw 
kvsIbvenwKv & dq«v t¹\nwKv  NnInÕbv¡v ap³]pw tijhpw s]cntUmssâänkv  tcmKnIfnepw,  
lotamUbmenknkv sN¿p¶ s]cntUmssâänkvtcmKnIfnepw D−mIp¶    kn---dnbmIv«nhv t{]m«o\nepw  Ccp¼v  
kqNnIIÄ --epw hcp¶ hyXymkw.  
 
8. KthjWw \S¯m\pÅ \ymboIcWw 
 kvsIbvenwKv& dq«v t¹\nwKv  NnInÕ _mÎocnbIfpsS Afhp Ipdbv¡pIbpw  AXphgn kn-- -
dnbmIv«nhv t{]m«o³ IpdbpIbpw kod¯nseAbÀ¬, t«m«Â AbÀ¬ ss_³UnwKv I¸mÊnÁn, ^dn«n³ 
Afhv  IqSpIbpw s]cntUm³jy¯nsâ BtcmKy¯ns\ sa¨s¸Sp¯pIbpw sN¿p¶p 
 
9. ]T\ coXn  
 ]T\¯nsâ `mKambn hyàn¡v Hcp \¼À \ÂIp¶XmWv.   
 \n§fpsS apgph³ hnhc§fpaS§nb tIkv NmÀ«v tcJs¸Sp¯p¶XmWv. Bhiysa¦nÂ ]cntim[\   
\S¯s¸Sp¶XmWv. Bhiym\pkcWambn Nn{X§Ä FSp¡s¸Sp¶XmWv. 
 s]cntbmtUm³jy¯nsâ ]cntim[\thfbnÂ 5 Fw.FÂ càw Hcp kndn©pw \oSnepw D]tbmKn v¨ 
tiJcn v¨ kn---dnbmIv«nhv t{]m«o³,kod¯nseAbÀ¬, t«m«Â AbÀ¬ ss_³UnwKv I¸mÊnÁn, 
^dn«n³ AfhvI¬Sp]nSn¡p¶Xmbncn¡pw. 
 càw tiJcn¡p¶Xv cmhnse 8 aWn¡pw 10aWn¡pw at²ybmbncn¡pw.  
 AXn\ptijw kvsIbnenwKv & dq«v¹m\nwKv F¶ NnInÕ sN¿p¶Xmbncn¡pw.  
 Hcpamk¯n\ptijw \n§fpsS s]cntbmtUm³jys¯ ]cntim[n¡pIbpw 5 Fw.FÂ. càw 
tiJcn¡pIbpw sN¿pw.  
 tiJcn¨ càw kn---dnbmIv«nhv t{]m«o³,kod¯nseAbÀ¬, t«m«Â AbÀ¬ ss_³UnwKv I¸mÊnÁn, 
^dn«n³ AfhvI¬Sp]nSn¡m³ D]tbmKn¡p¶Xmbncn¡pw. 
 
10. {]Xo£n¡p¶ A]IS km²yXIÄ   þ  
Cu ]T\¯nsâ {]hÀ¯\coXn aqeapÅ A]IS km[yX hfsc IpdhmWv. 
apdnhnÂ\nt¶m, sXmen¡SnbnÂ \nt¶m DÅ sNdnb  cà{kmhw, ho¡w, sNdnb thZ\ 
F¶nhbmWv A]IS  km[yXIÄ. Ch kqNnh¨ kvYe¯nÂ sNdnb k½À±w 
sNep¯nbmÂ km[pIcn¡s¸Spw.  
  
11. Cu ]T\¯nÂ ]s¦Sp¡p¶XpsIm−v F\n¡v Fs´¦nepw  D]tbmKapt−m ? 
 \n§Ä¡v t\cn«v Hcp D]tbmKhpw CÃ. 
 
12. Rm³ Cu ]T\¯nÂ ]s¦Sp¡p¶ hnhcw clkyambn hbv¡ptam ? 
 \n§fnÂ \n¶v  tiJcn¡p¶  FÃm hnhc§fpw  clkyambn hbv¡p¶Xmbncn¡pw \n§sf 
]änbpÅ hnhc§Ä BtcmSpw shfns¸Sp¯p¶Xmbncn¡nÃ.  `mhnbnÂ Cu ]T\w imkv{XteJ\ambn 
{]kn²oIcn¡pt¼mÄ \n§fpsS t]cn\p ]Icw tImUv BWv D]tbmKn¡pI.  
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13. Fs¶ F´psIm−v Cu ]T\¯nÂ DÄs¸Sp¯n ? 
 \n§Ä¡v s]cntUmssâänkvF¶ AkpJw DÅXpsIm−v \n§sf Cu ]T\¯nÂ 
DÄs]Sp¯nbncn¡p¶p. 
 
14. F{X BfpIÄ Cu ]T\¯nÂ DÄs¸Sp¶p.   60 
 
15. \ã]cnlmc DS¼Sn  
 ]T\hnt[bambn GsX¦nepw Xc¯nÂ tcmKw k¦oÀ®ambmÂ tcmKnsb Cu Øm]\¯nÂ 
hnZKvZNnInÕbv¡v hnt[b\m¡p¶XmWv.  
 
16. GsX¦nepw hn[¯nÂ thX\w e`n¡ptam : CÃ 
 
17. Ft¸mÄ thWsa¦nepw  F\n¡v  Cu ]T\¯nÂ \n¶v  ]n³amdmtam  
 
 Cu ]T\¯nÂ  ]s¦Sp¡Wtam th−tbm F¶p Xocpam\n¡m\pÅ ]qÀ®  AhImiw 
\n§Ä¡p−v.  \n§Ä CXnÂ  ]s¦Sp¡phm³ Xocpam\n¨mÂ  Hcp k½X]{X¯nÂ H¸n«v \ÂtI−Xp−v. 
Cu ]T\¯nÂ  \n¶v GXp kabhpw ]n³hm§m\pÅ  kzmX{´yhpw \n§Ä¡p−v.  CXv \n§fpsS  aäp 
NnInÕIsf bmsXmcp hn[¯nepw _m[n¡p¶Xmbncn¡nÃ.  
 
18. Cu KthjW¯nsâ ^eambn ]pXnb Fs´¦nepw  Is−¯epIfps−¦nÂ 
AXv Fs¶ Adnbn¡ptam ? 
 
 Cu ]T\¯nsâ  Is−¯epIÄ ]T\ Ahkm\w \n§sf Adnbn¡p¶Xmbncn¡pw.  
 
19. Cu ]T\¯nsâ  kab ssZÀLyw F{XbmWv ? 
 
 GItZiw 6 amkw  
 
20. CXp-am-bn-_-Ô-s -¸Sm¯ Gs´-¦nepw hnh-c-§Ä Bh-iy-apt−m    þ CÃ 
 
21. IqSpXÂ  hnhc§Ä¡mbn Xmsg ]dbp¶hsc \n§Ä¡v  _Ôs¸Smhp¶XmWv. 
 
    tUm. ioXÄ tat\m³.hn 
    t]mÌp{KmPpthäv 
    Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv   
    {io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kv, 
    IpetiJcw þ 629 161. 
    t^m¬: 9445678206 
    CsabnÂ :sheethel.menon@gmail.com 
 
 
Øew:  
 
XobXn :  
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TeúLtTô[oLÞdÏ Bn®û]d Ï±jR RLYp  
 
 
AuTôokR TeúLtTô[oLú[, 
 CkR BWônf£«p ReLû[  DÓTÓj§dùLôs[ ªÏkR BoYjÕPu 
ØÝU]ÕPu LXkÕùLôs[ YkR YWúYtTô[oLû[ YWúYt¡ú\u.  ¿eLs CkR 
BWônf£«pTeùLÓjÕdùLôsYRtÏ Øu CkR BWônf£ GRtLôL  SPjRlTÓ¡\Õ 
GuTûR ùR°YôL ×¬kÕùLôs[úYiÓm. EeLÞdÏ úRûYVô] Aû]jÕ  
®TWeLÞm ¸úZ ùLôÓdLlThÓs[Õ.   CkR BWônf£«u êXm HtTÓm  
SuûULs, HúRàm  BTjÕLs Utßm ARtLôL Utßm GqYôß CkR BWônf£ 
úUtùLôs[lTÓm Øû\Lû[Ùm ùR¬®dLlThÓs[Õ.  C§p ùLôÓdLlThÓs[ 
®TWeLû[ ùR°YôL T¥jÕ  ×¬kÕ ùLôs[úYiÓm.  ¿eLs  BWônf£«p 
TeúLtTô[oL[ôL Jl×Rp  YZeÏYRtÏ  Øu×  EeLÞdÏ  HtTÓm  A±®Vp 
NôokR NkúRLeLs Utßm  BWônf£ NmTkRlThP NkúRLeLs Aû]jÕm CkR 
BWônf£«u GkR LôXLhPj§Ûm ¿eLs T¥Yj§p Ï±l©hP ST¬Pm úLhÓ 
ùR°ÜTÓj§dùLôs[Xôm.  
 
1. RûXûU BnYô[o: PôdPo. ºRs úUú]ôu. ® 
  ØÕLûX UôQ®, ùT¬úVôPôu¥dv Õû\ 
  c êLôm©Lô Tp UÚjÕYdLpí¬ Utßm UÚjÕYUû], 
  ÏXúNLWmþ629 161 
  9445678206 
  Sheethel.menon@gmail.com  
  
2.  Y¯Lôh¥«u ùTVo : PôdPo. AÚi NRô£Yu, Gm.¥.Gv. 
 úTWô£¬Vo, ùT¬úVôPôu¥dv Õû\ 
 c êLôm©Lô Tp UÚjÕYdLpí¬ Utßm UÚjÕYUû], 
 ÏXúNLWmþ629 161 
 ªu AgNp :sadasivan_arun@hotmail.com 
 ûLúT£ : 9847246961 
 
3. CûQ Y¯Lôh¥«u ùTVo: PôdPo. G­NùTj úLôµ 
 ØRuûU úTWô£¬Vo,  
 ùT¬úVôPôu¥dv Õû\ 
 c êLôm©Lô Tp UÚjÕYdLpí¬ Utßm UÚjÕYUû], 
 ÏXúNLWm:629 161 
 ªu AgNp :elizabethkoshi_dr@yahoo.com 
 ûLúT£ : 9447154335 
 
  UÚjÕYo. À]ô Ei¦d¡ÚxQu 
  CûQ úTWô£¬Vo, ùTôÕ SX UÚjÕYjÕû\, 
  c êLôm©Lô UÚjÕYd Lpí¬,ÏXúNLWm-629161 
  ûLúT£ : 9947777615 
  ªu AgNp :beena.unnikrishnan@gmail.com 
 
4. Lpí¬«u ùTVo : c êLôm©Lô Tp UÚjÕYdLpí¬ Utßm UÚjÕYUû], 
   ®.©.Gm. Lôm©[dv,  
   TP¨Xm, ÏXúNLWm: 629 161. 
 
5.  BWônf£«u RûXl× 
 vùL«­e & ñh©[ô²e¡tÏ Øu×m ©u×m  ùT¬úVôúPôuûPt±v  
úSôVô°L°Ûm, aQOlimbizq^q <^! osb<gqe<x! ùT¬úVôúPôuûPh¥v 
Ofibitqgtqz<! sq.vqbig<cu<! HOvim<ce<! lx<Xl<! -Vl<H! GxqâMgtqz<Wx<hMl; A[®u 
®j§VôNm. 
 Annexure 3 
 
6. Ï±dúLôs:  
 1995 ØRp 2014 YûW«Xô] ùY°«PlThÓs[®gOô] ×jRLeL°u 
CÚkÕ ùRokùRÓdLlThP ®YWeLs.  
 
7. Ma;tpd; nehf;fk; kw;Wk; Fwpf;nfhs;fs; 
CkR Ma;tpd; Fwpf;nfhs;,vùL«­e & ñh©[ô²e¡tÏ Øu×m ©u×m  
ùT¬úVôúPôuûPt±v  úSôVô°L°Ûm, aQOlimbizq^q <^! osb<gqe<x!
ùT¬úVôúPôuûPh¥v Ofibitqgtqz<! sq.vqbig<cu<! HOvim<bd; lx<Xl<! -Vl<H!
GxqâMgtqz<Wx<hMl<!A[®u ®j§VôNm. 
 
8. BWônf£ûV A±®Vp Ã§VôL Eß§TÓjRp: 
vùL«­e & ñh ©[ô²e £¡hûN Tôd¼¬VôdL°u A[ûY Ïû\dÏmnke<!
&zl<]Pukpy; sq.vqbig<cu<! HOvim<ce<A[ûY Ïû\dLÜm,-Vl<H! sk<K,! olik<k!
-Vl<Hsk<K!hqj{kqxe<!lx<Xl<!0hvqm<ce<!Ngqbux<jx!nkqghMk<kUl<!ARuY¯VôL 
ùT¬úVôPôuûPh¥³u  BúWôd¡V¨ûX ùUfNlTÓjRÜm ùNn¡\Õ.  
 
9. ùNnØû\ : 
• ReLs CkR BWônf£«p DÓThPôp, ReLÞdùLuß JÚ Gi 
YZeLlTÓm 
• EeL°u ØÝ ®YWeLs APe¡] úLv Nôoh GÝRlTÓm. 
úRûYùVu\ôp T¬úNôRû] SPjRlTÓm. úRûYdúLtT TPeLÞm 
GÓdLlTÓm.  
• ùT¬úVôPôuûPh¥v T¬úNôRû] úYû[«p 5ml CWjRm  GÓdLlTÓm. 
• Dsq!&zl<!-vk<kl<!wMg<gh<hMl</!-K!-vk<kk<kqz<!dt<tsq.vqbig<cu<!HOvim<ce<, 
-Vl<H! sk<K,! olik<k! -Vl<Hsk<K! hqj{kqxe<! lx<Xl<! 0hvqm<ce<! we<x!
u^<Kuqe<!ntjuBl<!hvqOsikqh<hkx<G!dhObigh<hMk<kh<hMl</ 
• CWjRm GÓlTÕ LôûX 8 U¦dÏm 10 U¦dÏm CûP«p GÓdLlTÓm.  
• ARu©\Ï vùL«­e & ñh l[ô²e Gu\ £¡hûN ùNnYRôÏm. 
• JÚ UôRj§tÏ ©\Ï EeLÞûPV ùT¬úVôúPôu¥`jûR T¬úNô§dL 5ml 
CWjRm GÓdLlTÓm. 
 
10. G§oTôodÏm TdL®û[ÜLs 
 ,r;bray;ghl;od; tpist[fs; rpwpa mstpyhd gpur;ridfisna Vw;gLj;JfpwJ. 
g[z; my;yJ njhYf;foapy; rpwpa mst[ ,uj;jk; btspg;gl;L mJ tPf;fkhf khwp typia 
Vw;gLj;jyhk;. Crp nghl;l gpw;ghL me;j ,lj;ij mGj;jkhf nja;j;J tpl;lhy; 
,g;gpur;rid tuhky; jLf;fyhk;. 
 
11. BWônf£«p DÓTÓYoLÞdÏ  G§oTôodÏm SuûULs  ?     
úSW¥ TVu GÕÜm CpûX. CÚl©àm ReLÞdÏ CWjR T¬úNôRû]dÏ  
EiPôÏm ùNX®û]  SôeLs;  HtßdùLôs¡ú\ôm.  
 
12.ReLû[l Tt±V ®YWes Aû]jÕm Sm©dûLdÏ E¬VRôL TôÕLôdLlTÓm 
? 
 CkR Bn®uêXm úSôVô°LÞdÏ AYoL°u úSôn Ï±jR ØuL¦lûT 
×¬kÕùLôs[ Ø¥Ùm.  
 
13.GRtLôL Sôu CkR BWônf£dÏ úRokùRÓdLlThúPu?    
EeLÞdÏ ùT¬úPôuûPh¥v úSôn CÚlT§]ôp EeLû[ CkR 
BnÜdÏ úRokùRÓdLlThÓs[Õ.  
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14. vj;jid ngh; ,t;thuha;r;rpapy; g';F bfhs;thh;fs; ? 60 
 
15. CkR BWônf£«p HúRàm ¾eÏ HtThPôp AÕ GqYôß DÓ ùNnVlTÓm?
 CkR BWônf£«]ôp  ReLÞdÏ  úSÚm GkR®R ®TÃReLÞdÏm GeLs 
ØRuûU  BWônf£Vô[o ARu ØÝ  UÚjÕY ùNX®û] HtßdùLôsYôo 
 
16. ,e;j Muha;r;rpapy; g';nfw;gjw;fhf bfhLf;fg;gLk; bjhif?,y;iy 
 
17. Sôu BWônf£«u CûP«p ®X¡d ùLôs[XôUô?  
 ReLÞdÏ CkR BWônf£«p TeÏ ùLôs[Üm ®XLÜm ØÝ ÑRk§Wm 
EiÓ.  BWônf£«p TeÏùLôsYRôÛm, CûP«p ®XÏYRôÛm ReLs 
£¡hûNdÏGkR®R Tô§l×m HtTPôÕ. 
 
18. VnjDk; g[jpa jfty;fnsh fz;Lgpog;g[fnsh ,t;thua;r;rpapy; fz;Lgpof;fg; gl;lhy; 
vd;dplk; tptuk; bjhptpf;fg;gLkh?Mk; 
 
19. GqY[Ü LôXm CkR BWônf£«p DÓTPúS¬Ùm ?BßUôRm  
 
20. ,t;thuha;r;rpiag; gw;wpa ,ju jfty;fs; ?,y;iy 
 
21. HúRàm ®YWm úYiÓùUu\ôp VôûW AÔL úYiÓm ? 
 
 ®YWm A±kÕùLôs[ Guû] RôWô[UôL ùRôPo×ùLôs[Xôm  
   
 PôdPo. ºRs úUú]ôu. ® 
 ØÕLûX UôQY®  
 ùT¬úVôPôu¥dv Õû\ 
 c êLôm©Lô Tp UÚjÕYdLpí¬ Utßm UÚjÕYUû], 
 ÏXúNLWmþ629 161 
 9445678206 
 Sheethel.menon@gmail.com  
 
 
 
CPm : 
úR§ :         
 
 
 
ØRuûU BWônf£Vô[¬u ûLùVôlTm 
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PARTICIPANTS CONSENT FORM 
 
The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. I agree not to restrict the use of 
any data or results that arise from this study provided such a use is only for scientific 
purpose(s). I have been given an information sheet giving details of the study. I fully 
consent to participate in the study titled‘Effect of nonsurgical periodontal therapy on 
C-reactive protein and iron indices in haemodialysis patients with chronic 
periodontitis’ 
Serial no / Reference no:        
Name of the participant:        
Address of the participant: 
Contact number of the participant: 
Signature of the participant: 
Witnesses:      
1. 
2. 
Date: 
Place 
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k½X]{Xw 
 
 
Cu ]T\s¯ ]änbpÅ FÃm Imcy§fpw F\n¡v ]dªv a\Ênem¡n XcnIbpw AXnsâ Hcp 
]IÀ¸v F\n¡p \ÂIpIbpw sNbvXn«p−v.  Cu ]T\w KthjW¯n\mbn DÅXmsW¶pw F\n¡v  CXnÂ 
\n¶v  t\cn«v  Hcp ^ehpw D−mInsÃ¶pw Rm³ a\Ênem¡p¶p.  Cu ]T\¯nsâ  coXnbpw Dt±ihpw 
F\n¡v  a\Ênem¡n X¶n«p−v.  AXp t]mse  F\n¡v kwib§Ä tNmZn¡m³  Ahkc§Ä  
e`n¨n«pap−v.  CXnÂ ]s¦Sp¡m\pw  ]s¦Sp¡mXncn¡m\pw  DÅ AhImiw  F\n¡ps−¶pw  
AXpt]mse  ]T\¯nsâ GXp L«¯nepw  CXnÂ \n¶v ]n³h§m\pÅ kzmX{´yhpw F\n¡ps−¶pw  
Rm³ a\Ênem¡p¶p. Cu ]T\¯nÂ ]s¦Sp¡p¶XpsImt−m, ]s¦Sp¡m¯XpsImt−m Fsâ aäp 
NnInÕIsf _m[n¡p¶XsÃ¶v Rm³  Andbp¶p. “kvsIbvenwKv & dq«v t¹\nwKv  NnInÕbv¡v ap³]pw 
tijhpw s]cntUmssâänkv  tcmKnIfnepw,  lotamUbmenknkv sN¿p¶ s]cntUmssâänkvtcmKnIfnepw 
D−mIp¶    kn-- -dnbmIv«nhv t{]m«o\nepw  A\oanbm- -epw hcp¶ hyXymkw.” F¶ KthjW¯nÂ 
]s¦Sp¡p¶Xn\pw CXnsâ ^e§Ä imkv{XteJ\¯nÂ {]kn²oIcn¡p¶Xn\pw F\n¡v k½XamsW¶v 
Rm³ CXn\mÂ Andbn¨psImÅp¶p.  
 
kocnbÂ \¼À / d^d³kv \¼À : 
]s¦Sp¡p¶ Bfnsâ t]cv : 
taÂhnemkw : 
t^m¬ \¼À :  
 
            H¸v / hnceSbmfw 
km£n :   
    
Øew : 
XobXn  
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Jl×Rp T¥Ym 
 
  
CkR BWônf£«u RLYpLs Aû]jÕm Gu²Pm ùR°YôL 
GÝjÕêXm ®[dLlThÓs[Õ. CkR BWônf£«u Ø¥ÜLs G]dÏ 
úSW¥VôL  TVuTWô®hPôÛm UÚjÕYjÕû\«u  Øuú]t\j§tÏ  
TVuTÓm  GuTûR A±úYu.  CqYôWôn£ûVl Tt± Sôu ùR°YôL 
×¬kÕd ùLôiÓsú[u.   Sôu Rô]ôL ØuYkÕ C§p TeÏl ùTß¡ú\u. 
GuTûR A±úYu.  C§­ÚkÕ GkR úSWØm GdLôWQØm  á\ôUp  
YkRôÛm CkR UÚjÕYUû]«p  G]dÏ  ¡ûPdÏm UÚjÕY ER® 
Gq®Rj§Ûm Tô§dLlTPôÕ GuTûRÙm A±úYu.  CqYôWônf£«u  
êXm YÚm Ø¥ÜLs Utßm  RLYpLû[  A±®VpÕû\«u  
TVuTôÓLÞdÏ  (UhÓúU) ETúVôLlTh¥dùLôs[ NmU§d¡ú\u.  
G]dÏ  CqYôWônf£ûVl Tt±V  ®¬Yô] RLYpLs APe¡V  T¥Ym 
RWlThÓs[Õ.  
 Sôu “vùL«­e & ñh©[ô²e¡tÏ Øu×m ©u×m  
ùT¬úVôúPôuûPt±v  úSôVô°L°Ûm, aQOlimbizq^q^<! osb<gqe<x!
ùT¬úVôúPôuûPh¥v Ofibitqgtqz<!sq.vqbig<cu<!HOvim<bd; kw;Wk; ,Uk;G 
FwpâLfspy;Vw;gLk; A[®u ®j§VôNm” Gu¡\ CqYôWônf£«p  
TeúLtL ØÝU]ÕPu  NmU§d¡ú\u.  
 
Ï±l× Gi : 
 
ùTVo : 
 
ØLY¬ : 
 
 
ùRôûXúT£ Gi :       ûLùVôlTm 
 
 
Nôh£   1 
 
 
 
 2  
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SREEMOOKAMBIKA INSTITUTE OF DENTAL SCIENCES 
CASE RECORD FORM 
 
 Title of the short study: ‘Effect of nonsurgical periodontal therapy on C-reactive 
protein and iron indices in haemodialysis patients with chronic periodontitis’ 
 
 
 
 
 
Smoking status: 
Weight:                            Height:                                    BMI: 
Blood Pressure     Systolic:                                   Diastolic: 
Renal and Hematological Parameters 
CRP  
Serum Iron  
TIBC  
Transferrin saturation  
Serum Ferritin  
Hb  
ESR  
Albumin  
Creatinine  
GFR  
 
Medical history 
a) If patient is under haemodialysis: 
Dialysis duration: 
NAME:                                            DATE:   PHONE NUMBER:  
 AGE:                     SEX:   ADDRESS:  
   
INITIAL RECORDING (T0) 
 Annexure 5 
Clinical Parameters 
Number of teeth: 
PLAQUE INDEX 
                                                                                                
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                                                                
                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
Plaque Index Score: 
GINGIVAL INDEX 
                                                                                                
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                                                                
                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
Gingival Index Score: 
Bleeding on Probing:  
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
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PROBING POCKET DEPTH 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
 
GINGIVAL RECESSION/GINGIVAL ENLARGEMENT 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
 
CLINICAL ATTACHMENT LEVEL 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
 
Treatment done:-                                                                                                  
                                 Signature of Investigator 
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30 DAYS POST OPERATIVE RECORDING(T1) 
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Treatment done:-                                                                                                  
                                 Signature of Investigator 
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Renal and Hematological Parameters 
CRP  
Serum Iron  
TIBC  
Transferrin saturation  
Serum Ferritin  
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ESR  
Albumin  
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Clinical Parameters 
Number of teeth: 
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Plaque Index Score: 
 
 
 
90 DAYS POST OPERATIVE RECORDING(T2) 
 Annexure 5 
GINGIVAL INDEX 
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Treatment done:-                                                                                                  
                                 Signature of Investigator 
Annexure 6 
Group 1(Haemodialysis<1 year) 
 
 
 
Sl. No Name Age Sex BMI(kg/m2) BP(Sys/Dia) No of teeth present 
1 Paulraj 52 M 19.921 `132/96 30 
2 Sunder 55 M 21.60 140/96 24 
3 Saraswathy 59 F 2573 136/96 22 
4 Ajith 41 M 26.5 144/100 27 
5 Vikraman 62 M 20.55 138/96 31 
6 Kala 34 F 22.07 130/82 29 
7 Sivalingam 54 M 25.8 132/90 30 
8 Nainar 65 M 20.31 138/100 28 
9 Rathnakumar 50 M 23.80 132/92 23 
10 Fathima 35 F 20.56 136/88 32 
11 Margaret 60 F 24.69 138/96 22 
12 George 53 M 20.95 132/90 30 
13 Thankapandi 61 M 22.4 138/90 29 
14 Dasan 51 M 24.30 130/94 22 
15 Balakrishnan 58 M 20.31 138/96 31 
16 Dennison 45 M 20.51 136/94 24 
17 Gabriel 45 M 23.23 136/96 32 
18 Suresh 36 M 16.73 134/96 32 
19 John 44 M 18.59 136/92 26 
20 George 63 M 26.56 140/96 23 
 
 
 
 
 
 
Annexure 6 
Group 2(Haemodialysis>1 year) 
 
 
 
Sl. No Name Age Sex BMI(kg/m2) BP(Sys/Dia) No of teeth present 
1 Ponnappan 67 M 24.63 138/94 23 
2 Masilamani 65 M 22.05 136/96 26 
3 Devadhas 54 M 24.38 130/90 29 
4 Vijayakumar 30 M 19.87 136/94 32 
5 Nazeema 46 F 24.34 140/96 27 
6 Vijayakumar 50 M 23.11 138/96 28 
7 Mani 58 M 22.36 138/94 23 
8 Natarajan 64 M 24.25 136/90 23 
9 Justin 36 M 22.40 136/94 28 
10 Brightdas 50 M 22.86 138/92 30 
11 Aruldas 43 M 22.65 140/96 30 
12 Kanakaraj 45 M 22.86 132/92 31 
13 Subraman 61 M 23.23 136/94 32 
14 Reymond 42 M 21.707 138/90 32 
15 Merlin 28 F 21.30 130/90 30 
16 Baby Girija 56 F 23.92 140/98 22 
17 Thapamani 50 M 26.61 136/86 24 
18 Ganeshan 64 M 23.04 134/90 20 
19 Albin Jose 32 M 24.5 140/96 29 
20 Marianesan 57 M 24.6 138/94 32 
 
 
 
 
 
 
Annexure 6 
Group 3(Chronic Periodontitis) 
 
 
Sl. No Name Age Sex BMI(kg/m2) BP(Sys/Dia) No of teeth present 
1 Sandhya 28 F 21.35 120/84 30 
2 Kaladevi 49 F 20.84 120/82 28 
3 Ganesh 33 M 21.88 120/80 29 
4 Nalini 41 F 24.2 110/70 27 
5 Syamala 46 F 19.69 110/80 30 
6 Ratheesh 44 M 26.3 122/82 25 
7 Marybai 40 F 21.6 122/80 22 
8 Annamma 55 F 25.51 126/84 28 
9 Gopi 54 M 26.67 120/80 30 
10 Shikha 35 F 24.91 120/80 29 
11 Anandaroopan 27 M 23.91 112/80 31 
12 Mary 40 F 23.62 110/82 26 
13 Sreekumar 55 M 24.44 110/70 31 
14 Pushpakaran 51 M 25.3 130/86 21 
15 Suji 33 F 26.34 120/80 23 
16 Vijila 38 F 24.69 126/82 30 
17 Lekshmi 40 F 21.48 120/80 30 
18 Saritha 29 F 18.28 110/86 31 
19 Jayanthi 43 F 19.28 120/80 31 
20 Jerald 46 M 19.72 120/80 31 
 
 
 
 
Annexure 6 
Group 1(Haemodialysis<1 year) 
Sl NO Name 
Plaque index Bleeding on Probing Gingival index 
T0 T1 T2 T0 T1 T2 T0 T1 T2 
1 Paulraj 1.35 1.33 1.31 32.7 23.8 21.1 1.41 1.36 1.31 
2 Sunder 2.4 1.70 1.67 29.1 22.9 20.1 1.42 1.45 1.34 
3 Saraswathy 1.28 0.63 1.4 34.09 28.78 21.9 1.44 1.17 1.16 
4 Ajith 0.66 0.57 0.55 29 22 24.07 1.34 1.03 1.02 
5 Vikraman 2.32 1.58 1.48 36 28.4 26.3 1.56 1.41 1.33 
6 Kala 2.44 1.49 1.70 43.6 38.5 28.7 1.72 1.52 1.39 
7 Sivalingam 1.95 1.66 1.67 22.7 18.8 14.4 1.35 1.28 1.35 
8 Nainar 1.9 1.64 1.58 27 28.4 27.3 1.71 1.36 1.28 
9 Rathnakumar 2.54 1.60 1.19 73.9 42.7 24.6 2.53 1.48 1.33 
10 Fathima 1.65 1.28 1.20 22.91 16.1 13.5 1.41 1.179 1.26 
11 Margaret 2.18 1.43 1.54 36.2 23.4 18.8 1.59 1.38 1.34 
12 George 1.63 1.4 1.4 36.6 32 26.1 1.5 1.41 1.32 
13 Thankapandi 1.80 1.40 1.34 32.1 30.4 17.2 1.46 1.39 1.34 
14 Dasan 2.19 1.45 1.42 38.63 29.5 24.2 1.82 1.36 1.375 
15 Balakrishnan 1.21 0.93 0.87 13.4 13.4 10.7 1.26 1.29 1.25 
16 Dennison 1.32 0.65 0.781 29.16 25.6 22.9 2 1.3 1.39 
17 Gabriel 1.44 1.40 1.38 36.9 25.5 19.79 1.53 1.46 1.35 
18 Suresh 1.52 1.48 1.46 34 33 33.3 1.63 1.57 1.37 
19 John 2.3 1.49 1.43 41.2 28.2 21.1 1.63 1.41 1.35 
20 George 1.59 1.63 1.47 34.05 28.2 24.6 1.48 1.39 1.31 
 
Annexure 6 
Sl NO Name Probing pocket depth Clinical Attachment Level T0 T1 T2 T0 T1 T2 
1 Paulraj 2.86 2.81 2.72 3.2 3.02 3.1 
2 Sunder 2.57 2.62 2.34 3.95 3.48 3.46 
3 Saraswathy 3.18 2.75 2.62 3.24 3.21 3.09 
4 Ajith 2.95 2.54 2.50 3.19 2.79 2.73 
5 Vikraman 2.74 2.66 2.51 3.94 3.59 3.39 
6 Kala 2.97 2.85 2.68 3.02 2.89 2.73 
7 Sivalingam 2.73 2.67 2.64 2.79 2.73 2.71 
8 Nainar 3.34 2.77 2.69 3.39 2.81 2.72 
9 Rathnakumar 3.54 3.39 3.23 3.97 3.72 3.52 
10 Fathima 2.60 2.16 2.46 2.66 2.21 2.48 
11 Margaret 2.45 2.48 2.42 2.75 2.80 2.77 
12 George 3.47 3.49 3.23 3.73 3.74 3.39 
13 Thankapandi 2.31 2.63 2.49 2.45 2.72 2.56 
14 Dasan 2.91 2.43 2.52 5.08 4.96 4.67 
15 Balakrishnan 3.18 3.23 3.13 3.25 3.31 3.22 
16 Dennison 3.03 3.12 3.12 3.31 3.36 3.36 
17 Gabriel 3.09 2.72 2.63 3.43 3.06 2.93 
18 Suresh 3.16 2.65 2.63 3.05 2.99 2.91 
19 John 2.7 2.63 2.53 3.53 3.371 3.23 
20 George 3.09 3.06 2.9 3.76 3.71 3.52 
Annexure 6 
Group 2(Haemodialysis>1 year) 
Sl NO Name 
Plaque index Bleeding on Probing Gingival index 
T0 T1 T2 T0 T1 T2 T0 T1 T2 
1 Ponnappan 2.02 1.58 1.92 60.14 45.6 42 1.75 1.59 1.69 
2 Masilamani 1.4 0.99 1.48 35.25 27.5 26.9 1.52 1.31 1.35 
3 Devadhas 1.74 1.5 1.64 43.6 39.08 33.9 1.72 1.46 1.44 
4 Vijayakumar 2.18 1.28 1.72 31.25 22.3 15.6 1.5 1.35 1.28 
5 Nazeema 1.5 0.93 0.86 19.1 16.04 13.5 1.26 1.12 1.20 
6 Vijayakumar 1.58 1.35 1.57 43.4 36.30 25 2.18 1.46 1.26 
7 Mani 1.55 1.52 1.36 39.13 28.9 23.9 1.76 1.41 1.33 
8 Natarajan 1.8 1.61 1.57 46.37 31.8 28.9 1.70 1.43 1.43 
9 Justin 1.75 1.4 0.84 30.95 25 17.2 1.41 1.34 1.13 
10 Brightdas 1.52 1.41 1.47 21.6 14.4 11.6 1.28 1.23 1.1 
11 Aruldas 1.98 1.43 1.41 23.8 21.6 18.3 1.37 1.3 1.31 
12 Kanakaraj 2.09 1.54 1.52 47.3 37.6 34.9 2.25 1.58 1.41 
13 Subraman 2.05 1.54 1.44 38.5 33.3 28.12 1.56 1.51 1.39 
14 Reymond 1.32 1.34 1.37 23.95 21.3 25.7 1.27 1.28 1.23 
15 Merlin 1.68 1.41 1.38 32.7 29.4 20.5 1.48 1.39 1.35 
16 Baby Girija 1.29 0.81 0.87 12.8 7 9 1.60 1.29 1.34 
17 Thapamani 2.07 1.61 1.68 43.05 31.9 27.08 1.62 1.44 1.45 
18 Ganeshan 1.81 1.4 1.53 43.3 32.5 30 1.47 1.43 1.36 
19 Albin Jose 1.81 1.59 1.32 9.7 8 7 1.13 1.17 1.19 
20 Marianesan 1.81 1.32 1.315 41.6 31.7 27.08 1.89 1.37 1.35 
 
Annexure 6 
Sl NO Name Probing pocket depth Clinical Attachment Level T0 T1 T2 T0 T1 T2 
1 Ponnappan 2.69 2.64 2.54 3.05 2.92 2.80 
2 Masilamani 3.43 3.28 3.44 3.52 3.35 3.51 
3 Devadhas 3.60 2.97 3.32 5.09 4.67 4.56 
4 Vijayakumar 2.93 2.80 2.56 3 2.86 2.62 
5 Nazeema 2.70 2.33 2.31 2.77 2.40 2.34 
6 Vijayakumar 3.35 3.22 3.13 3.71 3.63 3.45 
7 Mani 2.76 2.60 2.51 2.971 2.68 2.57 
8 Natarajan 4.31 4.20 4.26 5.5 5.20 5.35 
9 Justin 3.04 2.91 2.87 3.065 2.92 2.88 
10 Brightdas 2.56 2.3 2.3 2.62 2.43 2.41 
11 Aruldas 2.66 2.61 2.48 2.78 2.72 2.57 
12 Kanakaraj 2.67 2.65 2.63 3.33 3.33 3.2 
13 Subraman 2.65 2.78 2.53 2.71 2.74 2.58 
14 Reymond 2.92 2.70 2.69 3.05 2.84 2.80 
15 Merlin 3.02 3.05 2.94 3.08 3.1 2.99 
16 Baby Girija 2.90 2.70 2.62 2.96 2.78 2.70 
17 Thapamani 3.28 3.19 3.04 3.95 3.86 3.59 
18 Ganeshan 2.63 2.35 2.3 3.62 3.35 3.25 
19 Albin Jose 2.67 2.44 2.43 2.68 2.45 2.44 
20 Marianesan 2.85 2.76 2.73 3.71 3.02 2.94 
Annexure 6 
Group 3(Chronic Periodontitis) 
Sl NO Name 
Plaque index Bleeding on Probing Gingival index 
T0 T1 T2 T0 T1 T2 T0 T1 T2 
1 Sandhya 2.43 1.92 1.6 84.4 82 33.8 2.6 2.12 1.54 
2 Kaladevi 1.92 1.52 1.4 54 35.1 35.7 2.10 1.47 1.57 
3 Ganesh 1.86 1.73 1.54 52.8 37.9 29.3 2.10 1.64 1.41 
4 Nalini 1.52 1.38 1.38 37.03 27.7 24.6 1.47 1.38 1.34 
5 Syamala 1.70 1.42 1.62 30 23.8 21.6 1.47 1.27 1.36 
6 Ratheesh 1.86 1.38 1.4 45.3 42.6 19.3 1.72 1.49 1.3 
7 Marybai 2.55 1.48 1.28 62.8 40.1 24.2 1.93 1.51 1.29 
8 Annamma 1.72 0.99 1.37 30.95 21.4 15.4 1.44 1.26 1.16 
9 Gopi 2.30 1.55 1.33 47.7 40 26.6 2.33 1.56 1.4 
10 Shikha 1.80 1.52 1.5 55.1 26.4 28.7 1.56 1.32 0.91 
11 Anandaroopan 1.70 1.65 1.4 63.4 46.7 23.11 1.88 1.70 1.37 
12 Mary 1.42 1.27 0.98 41.02 23 19.87 1.43 1.26 1.25 
13 Sreekumar 1.19 1.45 1.37 31 32.2 22.5 1.18 1.45 1.29 
14 Pushpakaran 1.65 1.54 0.92 36.5 24.6 11.9 1.53 1.32 1.23 
15 Suji 1.62 0.93 1.02 35.5 21.7 18.8 1.54 1.34 1.32 
16 Vijila 2.0 1.45 1.40 45 30.5 23.8 1.67 1.37 1.36 
17 Lekshmi 1.21 1.5 1.5 48.3 33.3 23.3 1.7 1.38 1.3 
18 Saritha 1.79 1.67 1.45 38.17 24.19 23.11 1.49 1.29 1.27 
19 Jayanthi 1.71 1.68 1.516 56.9 44 24.7 1.73 1.53 1.5 
20 Jerald 1.87 1.37 1.20 24.1 15.5 13.9 1.33 1.25 1.16 
 
Annexure 6 
Sl NO Name Probing pocket depth Clinical Attachment Level T0 T1 T2 T0 T1 T2 
1 Sandhya 3.81 3.5 2.73 3.93 3.75 2.84 
2 Kaladevi 2.92 2.67 2.58 2.95 2.75 2.63 
3 Ganesh 2.85 2.71 2.84 3.04 2.88 3.04 
4 Nalini 2.73 2.69 2.96 3.20 3.17 3.38 
5 Syamala 2.93 2.78 2.55 3.14 3 2.75 
6 Ratheesh 3.59 3.34 3.21 3.90 3.64 3.45 
7 Marybai 4.06 3.75 3.62 4.88 4.50 4.22 
8 Annamma 2.69 2.82 2.61 2.73 2.87 2.67 
9 Gopi 2.87 2.87 2.86 3.16 3.16 3.11 
10 Shikha 2.68 2.74 2.70 2.86 2.90 2.85 
11 Anandaroopan 3.74 3.60 3.49 3.80 3.67 3.55 
12 Mary 2.70 2.69 2.76 2.78 2.77 2.84 
13 Sreekumar 2.94 3.01 2.81 3.24 3.18 3.04 
14 Pushpakaran 3.84 3.57 3.06 4.31 4.04 3.53 
15 Suji 2.26 2.143 2.04 2.39 2.154 2.05 
16 Vijila 3.52 3.48 3.32 3.7 3.73 3.47 
17 Lekshmi 3.31 3.21 3.08 3.62 3.53 3.38 
18 Saritha 2.63 2.5 2.49 2.74 2.58 2.5 
19 Jayanthi 3.59 3.49 3.37 4.04 3.94 3.80 
20 Jerald 2.48 2.5 2.5 3.01 3 2.96 
 
Annexure 6 
Group 1(Haemodialysis<1 year) 
 
Sl NO Name CRP(T0) (mg/L) 
CRP(T2) 
(mg/L) 
Serum 
iron(T0) 
(µg/dl) 
Serum 
iron(T2) 
(µg/dl) 
Serum 
TIBC(T0) 
(µg/dl) 
Serum 
TIBC(T2) 
(µg/dl) 
TSAT(T0) 
% 
TSAT(T2) 
% 
1 Paulraj 2.1 1 29.5 59 154 212 19.15 27.83 
2 Sunder 4 3.7 31.9 40 215.7 225 14.78 17.77 
3 Saraswathy 3.1 3 27.6 30 177.2 184.2 15.57 16.28 
4 Ajith 2 3.1 53.3 49 125.3 113.2 42.53 43.28 
5 Vikraman 4.8 5.6 31.4 46.6 177.6 189.4 17.68 24.60 
6 Kala 1.6 9.9 25.4 41.5 130.9 250.2 19.40 16.58 
7 Sivalingam 3.2 1.2 35.6 33.5 198.7 221.6 17.91 15.11 
8 Nainar 10 7 30.5 66.3 188.5 220.4 16.18 30.08 
9 Rathnakumar 14 10 40.5 51 201 231.2 20.1 22.05 
10 Fathima 12 7 54.3 64 165.1 189.5 32.88 33.77 
11 Margaret 14 10 45.1 41.4 261.5 251.3 17.24 16.47 
12 George 3.8 2.4 36.8 50.2 198.4 218.7 18.54 22.95 
13 Thankapandi 4.6 4.5 40.2 45.6 210.2 223.5 19.12 20.40 
14 Dasan 5.2 6 32.5 29 169.1 193 19.21 15.02 
15 Balakrishnan 12 9 30.1 35.2 215.1 235 13.99 14.97 
16 Dennison 7 5 46.7 72.9 174.3 210 26.79 34.71 
17 Gabriel 5.5 2.8 49.8 51 182.3 187 27.31 27.27 
18 Suresh 12.3 10.5 42.7 42 251.1 259 17 16.21 
19 John 25 21 35.8 37.4 126.1 131.3 28.39 28.48 
20 George 15 19 50.1 49.8 136.1 134.5 36.81 37.02 
Annexure 6 
 
Sl. No Name 
Serum 
ferritin 
(T0) 
(ng/mL) 
Serum 
ferritin 
(T2) 
(ng/mL) 
Hb(T0) 
(gm/dL) 
Hb(T2) 
(gm/dL) 
ESR(T0) 
(mm/Hr) 
ESR(T2) 
(mm/Hr) 
Serum 
albumin 
(T0) 
(gm/dL) 
Serum 
albumin (T2)  
(gm/dL) 
1 Paulraj 471.9 444 8.1 9 52 49 3.8 3.9 
2 Sunder 320.7 147.5 7.5 10.2 112 90 4.1 3.8 
3 Saraswathy 83 69 9.4 8.3 79 84 3.7 4 
4 Ajith 230 267 7.1 8.7 44 53 3.5 3.8 
5 Vikraman 306.1 864.1 8 9 90 69 3.7 3.9 
6 Kala 355.8 429.2 6 5.6 92 72 3.8 4 
7 Sivalingam 987.9 877 9.6 10.3 71 60 3.7 4.1 
8 Nainar 930 906.1 6.4 7.8 40 30 4 3.8 
9 Rathnakumar 987 856 10.9 11 81 77 3.8 4 
10 Fathima 587.1 1126.3 9.6 8.5 61 37 3.5 3.6 
11 Margaret 561 715.1 9.2 8.5 57 46 4.1 4.2 
12 George 467 450 10.1 6.2 59 90 4.9 3.7 
13 Thankapandi 368 334 12 12.7 66 45 4.3 3.9 
14 Dasan 278 246 8 9.3 36 33 4.1 3.8 
15 Balakrishnan 335 352 9.4 11 45 36 3.8 4.1 
16 Dennison 304 286.9 10 13.2 55 37 4 4.2 
17 Gabriel 413 401.6 9 9.8 60 76 3.8 4.1 
18 Suresh 260 289 10 12 79 66 4.1 4.4 
19 John 640 662.1 11.5 11 67 64 4 4.4 
20 George 290 284 9 8.7 82 75 3.8 3.9 
Annexure 6 
Group 1(Haemodialysis<1 year) 
 
 
 
Sl.No Name 
Serum 
creatinine 
(T0) 
(mg/dl) 
Serum 
creatinine 
(T2) 
(mg/dl) 
GFR(T0) 
(mL/ 
min/1.73m
2
) 
GFR(T2) 
(mL/min/ 
1.73m
2
) 
1 Paulraj 11.1 10.1 5 6 
2 Sunder 12.1 12.1 5 5 
3 Saraswathy 5.1 7 10 7 
4 Ajith 11.5 11 6 6 
5 Vikraman 7 7.3 9 8 
6 Kala 12 11.9 4 4 
7 Sivalingam 6.4 7.4 10 9 
8 Nainar 6.9 5.5 9 12 
9 Rathnakumar 9.5 10 7 6 
10 Fathima 9.3 8.5 6 6 
11 Margaret 8.5 8.6 5 5 
12 George 9.5 9.6 7 6 
13 Thankapandi 6.5 8 10 8 
14 Dasan 6.4 5 11 14 
15 Balakrishnan 7.8 6.7 8 10 
16 Dennison 8.2 11.6 8 5 
17 Gabriel 9.1 9.5 7 7 
18 Suresh 9.5 7.9 7 9 
19 John 8.3 7.9 8 9 
20 George 9.5 5.4 6 12 
 
 
 
 
Annexure 6 
Group 2(Haemodialysis>1 year) 
 
Sl NO Name CRP(T0) (mg/L) 
CRP(T2) 
(mg/L) 
Serum 
iron(T0) 
(µg/dl) 
Serum 
iron(T2) 
(µg/dl) 
Serum 
TIBC(T0) 
(µg/dl) 
Serum 
TIBC(T2) 
(µg/dl) 
TSAT(T0) 
% 
TSAT(T2) 
% 
1 Ponnappan 4.8 4.8 42.4 46 189 195.6 19.15 23.51 
2 Masilamani 5.1 18L 49.2 82 173 223 28.43 36.77 
3 Devadhas 3.2 4 51 59 136 152 37.5 38.81 
4 Vijayakumar 3.1 1.2 65 51 152 131.2 42.76 38.87 
5 Nazeema 2.2 1.5 39.9 41.9 158 161.2 25.25 25.99 
6 Vijayakumar 7 6.4 90 92 261.4 263.4 34.42 34.92 
7 Mani 2.4 4 49 51.4 109.7 113.9 44.66 45.12 
8 Natarajan 20 12 59 49.2 213.2 185.4 27.67 26.53 
9 Justin 4.2 5 50.1 47 181.2 173.9 27.64 27.02 
10 Brightdas 13 10 62 47 192 148 32.29 31.75 
11 Aruldas 4.8 4 49.3 49 170.3 176.8 28.94 27.71 
12 Kanakaraj 4 4.5 65 59 224.2 194.3 28.99 30.36 
13 Subraman 6 5.4 29 34 210 207.5 13.80 16.38 
14 Reymond 5 3.5 45.7 49 108.8 113.9 42 43.02 
15 Merlin 8.6 7.5 84 76 297 267 28.28 28.46 
16 Baby Girija 11 10.8 74.7 84.5 257.2 275 29.04 30.72 
17 Thapamani 10 6 38 43.1 187 199.4 20.3 21.6 
18 Ganeshan 30 27 56 40.5 171 170.2 32.7 23.79 
19 Albin Jose 7 5 39 40.1 142.7 137.4 27.33 29.18 
20 Marianesan 16 12 48 50.6 167.3 160.4 28.69 31.54 
Annexure 6 
 
Sl. No Name 
Serum 
ferritin 
(T0) 
(ng/mL) 
Serum 
ferritin 
(T2) 
(ng/mL) 
Hb(T0) 
(gm/dL) 
Hb(T2) 
(gm/dL) 
ESR(T0) 
(mm/Hr) 
ESR(T2) 
(mm/Hr) 
Serum 
albumin 
(T0) 
(gm/dL) 
Serum 
albumin 
(T2)  
(gm/dL) 
1 Ponnappan 188.4 106.3 8. 6 8.8 88 85 3.7 4 
2 Masilamani 181.1 784.1 9.2 10.2 41 63 4.1 4.5 
3 Devadhas 171 169 8.5 8.5 50 62 4 4 
4 Vijayakumar 238 245.2 5.4 7 57 48 3.7 3.9 
5 Nazeema 401.7 689.4 9.5 10.1 16 15 4.4 4.1 
6 Vijayakumar 360 349 7.8 6.8 67 54 3.8 3.6 
7 Mani 241.2 228 11.9 10.7 26 20 4.4 3.9 
8 Natarajan 537.5 484.9 11.7 11.9 20 28 4.2 4 
9 Justin 1278.5 1180 6.8 8.2 67 49 4 4.2 
10 Brightdas 430 640.6 9.8 6 38 36 4.6 4.3 
11 Aruldas 169.5 189 9.8 9.5 54 56 4.9 4.7 
12 Kanakaraj 276 266 9.9 8.7 72 67 3.8 4 
13 Subraman 1292.9 1240 9.7 10.2 69 64 4.5 4.2 
14 Reymond 647 638 7.7 7.5 67 35 4.4 4 
15 Merlin 347 366 10.1 11 77 68 3.7 3.6 
16 Baby Girija 366 381 6.6 8.1 65 72 3.8 3.9 
17 Thapamani 212 202.1 8.3 9.3 43 35 4.6 4.1 
18 Ganeshan 251.2 267.5 8.7 6.6 75 117 3.9 4 
19 Albin Jose 289 278 8.5 9.5 66 45 4 4 
20 Marianesan 678 692.1 6.4 6.6 63 57 3.7 3.9 
Annexure 6 
Group 2(Haemodialysis>1 year) 
 
 
Sl.No Name 
Serum 
creatinine 
(T0) 
(mg/dl) 
Serum 
creatinine 
(T2) 
(mg/dl) 
GFR(T0) 
(mL/ 
min/1.73m
2
) 
GFR(T2) 
(mL/min/ 
1.73m
2
) 
1 Ponnappan 6.7 6.8 9 9 
2 Masilamani 7.1 13.6 8 4 
3 Devadhas 9.1 10 7 6 
4 Vijayakumar 7.8 8.5 11 9 
5 Nazeema 4.2 5.7 12 8 
6 Vijayakumar 5.6 5.2 11 12 
7 Mani 6.4 10.4 9 5 
8 Natarajan 7.5 7 7 8 
9 Justin 3 4.1 26 18 
10 Brightdas 5.2 10.1 12 5 
11 Aruldas 4 6.4 17 10 
12 Kanakaraj 7.6 7.4 8 8 
13 Subraman 3.1 3 21 21 
14 Reymond 3.4 3.1 21 24 
15 Merlin 10.1 9 5 5 
16 Baby Girija 12 10.3 3 4 
17 Thapamani 10.4 11.2 5 5 
18 Ganeshan 3.2 3.5 19 17 
19 Albin Jose 8.6 19.5 7 5 
20 Marianesan 8.8 8.6 6 6 
 
 
 
 
 
Annexure 6 
Group 3(Chronic Periodontitis) 
 
Sl NO Name CRP(T0) (mg/L) 
CRP(T2) 
(mg/L) 
Serum 
iron(T0) 
(µg/dl) 
Serum 
iron(T2) 
(µg/dl) 
Serum 
TIBC(T0) 
(µg/dl) 
Serum 
TIBC(T2) 
(µg/dl) 
TSAT(T0) 
% 
TSAT(T2) 
% 
1 Sandhya 2.4 1.8 63 93.1 194 231.3 32.47 40.25 
2 Kaladevi 3.2 3.1 58 62 178.4 189 32.51 32.80 
3 Ganesh 2.1 1.8 65.1 69 234 241.2 27.82 28.60 
4 Nalini 2.2 1.4 49 54.5 234 264.3 20.94 20.62 
5 Syamala 2.6 1.8 69.4 85.1 345 240 20.11 35.45 
6 Ratheesh 2.7 2.2 77 72 197.2 186.3 39.04 38.64 
7 Marybai 2.8 1.9 55.8 65 266.7 293.5 20.92 22.14 
8 Annamma 3.5 3.1 50.3 53.4 278 265.4 18.09 20.12 
9 Gopi 3.5 3.6 68.7 57.9 402.4 412 17.07 14.05 
10 Shikha 2.6 2.1 75.4 78 306 321.4 24.64 24.19 
11 Anandaroopan 1.9 1.5 64.3 64 248.5 261.3 25.87 24.49 
12 Mary 1.2 2.1 80 82.7 215 227 37.2 36.43 
13 Sreekumar 1.3 1 83.2 88.1 186 194 44.73 45.41 
14 Pushpakaran 2.5 2 66.6 84.3 265.2 219.8 25.11 38.35 
15 Suji 2.4 1.9 86 62.5 269 185 31.9 33.7 
16 Vijila 2.3 1.6 89 92 280.2 274 31.76 33.5 
17 Lekshmi 2.3 1.4 46.3 43 143.7 129.6 32.21 33.17 
18 Saritha 3.2 2.4 79 74.5 196 180.3 40.30 41.32 
19 Jayanthi 2.7 2.4 63 59 220 195 28.6 30.25 
20 Jerald  2.6 2.8 72.6 70 165.2 157.8 43.94 44.35 
Annexure 6 
 
Sl. No Name 
Serum 
ferritin (T0) 
(ng/mL) 
Serum 
ferritin (T2) 
(ng/mL) 
Hb(T0) 
(gm/dL) 
Hb(T2) 
(gm/dL) 
ESR(T0) 
(mm/Hr) 
ESR(T2) 
(mm/Hr) 
Serum 
albumin 
(T0) 
(gm/dL) 
Serum 
albumin 
(T2)  
(gm/dL) 
1 Sandhya 21.2 15.6 14.1 13.2 4 4 4.2 4 
2 Kaladevi 71 67.5 12 12.1 27 20 4.2 4.1 
3 Ganesh 65.5 49 10 12.3 35 28 4 4.1 
4 Nalini 21.3 19.2 10.9 12.7 20 14 3.9 4.7 
5 Syamala 35.1 26 11 12.4 13 8 3.8 3.7 
6 Ratheesh 65 55 10.2 11 19 13 3.9 3.6 
7 Marybai 50.1 51.3 14.5 13.2 14 14 4.2 4 
8 Annamma 79.3 72.9 10.4 10.4 29 22 4.2 4 
9 Gopi 49.5 36 9.4 10.2 31 25 4.2 4.2 
10 Shikha 34 31 12.4 11.4 17 22 4.1 4.3 
11 Anandaroopan 22 16 11 12.1 19 25 4 4.2 
12 Mary 61 54.7 13 12 9 14 4.4 4.1 
13 Sreekumar 65 68 10.6 11.5 31 27 3.8 4 
14 Pushpakaran 90 90.6 13.2 13 14 10 4.4 4 
15 Suji 29.3 27 12.3 12.9 18 16 4 4 
16 Vijila 38.1 40.3 12 13.3 17 17 4.3 4.1 
17 Lekshmi 58 58 12.1 10 10 13 4 3.8 
18 Saritha 83 89.6 11 13.4 24 17 3.8 4.2 
19 Jayanthi 53.4 48.4 12.6 11.7 16 19 3.8 4.2 
20 Jerald  36.5 31.2 11.5 12 27 21 4 4 
 
Annexure 6 
 
Group 3(Chronic Periodontitis) 
 
 
Sl.No Name 
Serum 
creatinine 
(T0) 
(mg/dl) 
Serum 
creatinine 
(T2) 
(mg/dl) 
GFR(T0) 
(mL/ 
min/1.73m
2
) 
GFR(T2) 
(mL/min/ 
1.73m
2
) 
1 Sandhya 0.8 0.8 101 101 
2 Kaladevi 0.8 0.8 87 87 
3 Ganesh 0.9 0.6 112 132 
4 Nalini 0.7 0.7 108 108 
5 Syamala 0.7 0.6 104 110 
6 Ratheesh 0.6 0.6 122 122 
7 Marybai 0.9 0.7 80 109 
8 Annamma 1 0.9 64 72 
9 Gopi 0.9 0.9 96 96 
10 Shikha 0.8 0.7 96 113 
11 Anandaroopan 0.9 0.7 117 129 
12 Mary 0.9 0.8 80 93 
13 Sreekumar 0.7 0.7 107 107 
14 Pushpakaran 0.9 1 99 87 
15 Suji 0.8 0.7 97 114 
16 Vijila 0.6 0.7 116 110 
17 Lekshmi 0.8 0.8 93 93 
18 Saritha 0.9 0.8 87 100 
19 Jayanthi 0.6 0.6 112 112 
20 Jerald 0.7 0.7 113 113 
 
 
